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Abstract
Epithelial ovarian cancer (EOC) represents the most frequent cause of death in the United States
from a cancer involving the female genital tract. Contributing to the overall poor outcome in EOC
patients, are the metastases to the peritoneum and stroma that are common in this cancer. In one
study, cDNA microarray analysis was performed on fresh tissue to profile gene expression in
patients with EOC. This study showed a number of genes with significantly altered expression in
the pelvic peritoneum and stroma, and in the vicinity of EOC implants. These genes included those
encoding coagulation factors and regulatory proteins in the coagulation cascade and genes encoding
proteins associated with inflammatory responses. In addition to promoting the formation of blood
clots, coagulation factors exhibit many other biologic functions as well as tumorigenic functions, the
later including tumor cell proliferation, angiogenesis, invasion, and metastasis. Coagulation pathway
proteins involved in tumorigenesis consist of factor II (thrombin), thrombin receptor (protease-
activated receptors), factor III (tissue factor), factor VII, factor X and factor I (fibrinogen), and fibrin
and factor XIII. In a recent study we conducted, we found that factor XII, factor XI, and several
coagulation regulatory proteins, including heparin cofactor-II and epithelial protein C receptor
(EPCR), were also upregulated in the peritoneum of EOC.
In this review, we summarize evidence in support of a role for these factors in promoting tumor
cell progression and the formation of ascites. We also discuss the different roles of coagulation
factor pathways in the tumor and peritumoral microenvironments as they relate to angiogenesis,
proliferation, invasion, and metastasis. . Since inflammatory responses are another characteristic of
the peritoneum in EOC, we also discuss the linkage between the coagulation cascade and the
cytokines/chemokines involved in inflammation. Interleukin-8, which is considered an important
chemokine associated with tumor progression, appears to be a linkage point for coagulation and
inflammation in malignancy. Lastly, we review findings regarding the inflammatory process yielded
by certain clinical trials of agents that target members of the coagulation cascade in the treatment
of cancer. Current data suggest that disrupting certain elements of the coagulation and
inflammation processes in the tumor microenvironment could be a new biologic approach to
cancer therapeutics.
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An estimated 22,220 new cases of and 16,210 deaths from
epithelial ovarian cancer (EOC) will occur in 2005 [1].
EOC is insidious: 75% of patients present at an advanced
stage, in which metastasis to the peritoneal cavity lining is
characteristic. Peritoneal and serosal involvement is asso-
ciated overall with a poor patient outcome. The mecha-
nism of peritoneal seeding, spreading, and progression is
poorly understood. Direct contact of free-floating ovarian
tumor cells in the peritoneal cavity may place the perito-
neum at risk for metastatic spread. Other evidence of met-
astatic spread points to a surface epithelium origin of EOC
[2] or genetic instability of the stroma [3].
Evidence is mounting that an inflammatory process con-
tributes to tumor growth and metastasis to the perito-
neum in EOC [4,5]. This process is facilitated by cross talk
between tumor cells and the surrounding cellular stroma
[6]. Surgical findings from EOC frequently include
enhanced tumor vascularity with or without malignant
ascites. Microscopic examination may reveal an inflam-
matory infiltrate comprising different leukocyte popula-
tions [6]. The stroma associated with tumors may
resemble granulation tissue formed during wound heal-
ing [7]. The interaction of cancer cells with their surround-
ings might influence phenotypic alterations in the tumor.
For example, the presence of human breast tumor stromal
explants in mice may determine the formation of breast
cancer-like lesions [8].
In a recent study, we compared the transcriptional profile
of normal-appearing peritoneum and its adherent and
subjacent stroma in EOC patients with that of patients
with pathologically benign ovarian disease [3]. In our
study, we identified 402 genes differentially expressed
between malignant and benign peritoneum and 663
genes differentially expressed between malignant and
benign stroma. No significant differences in gene expres-
sion between malignant peritoneum and malignant
stroma were observed, which suggests that the transcrip-
tional changes induced by the malignant condition over-
lapped at least partly. Our preliminary analysis indicated
that the gene profile of peritoneal structures might be
affected by the presence of EOC cells [3]. We found it
interesting that the genes included those linked to inflam-
matory processes and a number were linked to the coagu-
lation pathway. An examination of these two processes at
the gene transcript level suggests a number of possible
links between coagulation and inflammation. In this
paper, we discuss the different roles of coagulation factor
pathways as they relate to angiogenesis, proliferation,
invasion, and metastasis in the tumor and peritumoral
microenvironment.
Coagulation and cancer development
The history of a known association between coagulation
and cancer dates back to 1865, when Armand Trousseau
observed that patients who presented with idiopathic
venous thromboembolism frequently had an underlying
occult cancer and vice versa [9]. The association has only
recently become more apparent. Previously, researchers
focused on how tumors activate blood coagulation and
how to overcome it. However, the underlying mechanism
by which coagulation factors promote tumor cell growth,
invasion, metastasis, and angiogenesis has become a hot
topic in the field of cancer research. Some coagulation fac-
tors that displaya role in tumor progression have been
reviewed [10]. The most frequent reports on coagulant
proteins and cancer interactions include factor III (tissue
factor; TF) [11], TF-factor VIIa [12,13], factor Xa [14], fac-
tor IIa (thrombin)-factorII receptors (also called proease-
activated receptors (PARs) [15], and factor XIIIa-factor Ia
(fibrin) (Table 1) [16]. Two cascades, one intrinsic and the
other extrinsic, lead to the formation of a fibrin clot.
Although they are initiated by distinct events, the two cas-
cades converge on a common pathway that includes
thrombin, PARs, and fibrin and lead to clot formation.
The intrinsic cascade, which is initiated when contact is
made between blood and exposed endothelial cell (EC)
surface, requires the clotting factors VIII, IX, XI, and XII.
Also required are the proteins prekallikrein and high-
molecular-weight kininogen and Ca2+ and phospholipids
secreted from platelets. The extrinsic coagulation cascade
is initiated at the site of injury in response to the release of
TF. Activated factor X is the site at which the intrinsic and
extrinsic coagulation cascades converge. TF and factor VIIa
contribute to the extrinsic cascade and possibly to the
development of cancer. Other factors from the intrinsic
pathway, such as factors XI and XII, have not yet been
directly implicated in cancer progression. Our recent anal-
ysis of the gene expression profile in EOC has revealed
increased levels of factor XI and factor XII transcripts in
the peritoneum of EOC patients [3]. These findings sug-
gest that the intrinsic cascade might promote ovarian can-
cer cell metastasis in the peritoneal cavity. We also showed
that the serine proteinase inhibitor D1 (SERPIND1),
which inhibits plasmin, tissue kallikrein, and factor XIa,
were downregulated [3].
Blood coagulation cascades can be activated by different
mechanisms and to different levels in cancer patients. The
alterations range from subtle abnormalities in laboratory
tests to clinically overt thrombosis and disseminated
intravascular coagulation [17]. Up to 50% of all cancer
patients and 90% of those with metastases exhibit hemo-
static abnormalities [17]. These abnormalities may be
reflected in the dominance of the tumor cell-associated
procoagulant pathway, which leads to thrombin genera-
tion and hypercoagulation. Similar observations werePage 2 of 20
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process. Ovarian cancer cells may also express TFs and the
other coagulation components that generate local
thrombin, as indicated by the conversion of fibrinogen to
fibrin [18]. Fibrin has been found on ECs and the surface
of ovarian tumor cells and nodules [18]. Coagulation acti-
vation in malignancy may be triggered by direct or indi-
rect mechanisms. Direct activation of blood coagulation
by the induction of thrombin may occur through the
activity of tumor cell procoagulation, whereas indirect
activation may occur through the production of tumor-
associated cytokines that trigger TF production by host
macrophages (MAs) or ECs. The coagulation pathway
components may contribute to tumor cell proliferation,
invasion, and metastasis [10], although these alterations
could also be a consequence of advanced disease [19].
Factor XII and the kallikrein family (positive feedback loop)
Factor XII is a procoagulant protein that participates
directly or indirectly in activating the intrinsic clotting
pathway. The structure of factor XII, which has been
inferred from its DNA and amino acid sequences, include
two epidermal growth factor (EGF) homologous domains
in the amino-terminal region [20]. This type of structure
suggests that factor XII might mimic EGF biological char-
acteristics and act as a growth factor. One study showed
that factor XII had mitogenic effects on the HepG2 human
hepatocellular carcinoma cell line and, similar to EGF,
stimulated tumor cell proliferation [20].
Assembly of contact phase components results in the con-
version of prekallikrein to kallikrein, which in turn acti-
vates factor XII to factor XIIa. Factor XIIa then hydrolyzes
more prekallikrein to kallikrein, thereby establishing a
reciprocal activation loop. Factor XIIa also activates factor
XI to factor XIa and leads to the release of bradykinin, a
potent vasodilator, from high-molecular-weight kinino-
gen. The human kallikreins (hK) are a subfamily of the
serine protease enzyme family [21], which consists of pro-
teolytic enzymes important to various physiologic proc-
esses, such as digestion, coagulation, fibrinolysis,
apoptosis, cell migration, tissue remodeling, and inflam-
mation [21]. The hK gene family, which includes 15 mem-
bers (hK1-hK15) clustered in a 300-kb region on
chromosome 19q13.4, could be altered in cancer. A
number of studies have reported increased amounts of
kallikrein transcripts or proteins in cancer cells, particu-
larly adenocarcinomas derived from steroid hormone-reg-
ulated tissues [21]. At least 11 kallikrein genes or proteins
have been found to be overexpressed in EOC; they are hK4
[22], hK5 [23,24], hK6 [25,26], hK7 [27], hK8 [28,29],
hK9 [30], hK10 [31-33], hK11 [34-37], hK13 [38,39],
hK14 [40,41], and hK15 [42] mRNA or protein in ovarian
cancer tissue, cell lines, serum, and tumor ascites fluid
(Table 2). A recent gene microarray analysis on ovarian
cancer tissue found overexpression of hK2 and hK3 [43].
Overexpression of hK8 [28,29], hK9 [30], hK11 [34,35],
hK13 [38,39], and hK14 [41] have been reported as inde-
pendent variables associated with longer progression-free
and overall survival. Another study found hK11 to be an
Table 1: Coagulation factors and the associated regulatory proteins in EOC
Coagulation factors Effects
Tissue factor (TF) ↑ Promoting angiogenesis by activation of MAPK[73] and protein C kinase C-dependent signaling[76]; TF-
PAR2 selectively synergizes with PDGF-BB to enhance to metastasis in lymphnodes[78].
Promoting invasion and metastasis by the activation of P21Ras and P42/P44 MAPK pathway to inhibit 
apoptosis[14]; overexpressing growth factors and chemokines (i.e. IL-8)[13].
TF-VII-PAR2 ↑ Promoting angiogenesis, invasion, and metastasis by clotting-independent mechanism[77] in presence of 
inflammatory cytokines
Factor X ↑ Forming complex with TF-VIIa to promote tumor angiogenesis and metastasis[14]
Thrombin/PAR1 ↑ Promoting angiogenesis by inhibiting EC migration to collagen type IV or to laminin[99]; upregulating VEGF 
expression[100].
Promoting invasion and metastasis depended on at least 6 mechanisms (text)
Fibrinogen/fibrin ↑ Stimulating angiogenesis; the fibrin gel matrix facilitating tumor metastasis; increasing plasma exudates to 
form ascites[129, 130, 132].
Factor XII/XI ↑ Positive feedback on human kallikreins system
Factor XIII ↑ Form stable fibrin
Regulatory proteins
Heparin cofactor II ↑ Produce chemoattractant peptide for MAs migration.
Endothelial protein C receptor ↑ Intensifying APC-PAR1 signal transduction [205] and contributing to antiapoptosis in tumor.
Tissue factor pathway inhibitor ↓ Loss of control of tumor growth and metastasis by activating Factor Xa and increasing Factor Xa-PAR2 
signaling[81].
Tissue factor pathway inhibitor-2 ↓ Loss of Inhibiting TF-VIIa complex and various protease but not Factor Xa;
Loss of antiangiogenesis and antimetastasis.Page 3 of 20
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been linked to progression in EOC (Table 2). Although
many hKs are overexpressed in EOC tissues and in ascites,
it is unknown whether this phenomenon reflects
increased proteolytic activity because of the heterogeneity
of hK forms and the presence of active enzymes found in
the extracelluar matrix (ECM). This apparent paradox in
which the clinical outcome differs with different hKs
might be due to different biologic roles of hKs in the
tumor progression process, either stimulating or inhibit-
ing the development of the tumor and its microenviron-
ment. hK-mediated pericellular proteolysis in the ECM
might help regulate tumor cell growth, angiogenesis, inva-
sion, and metastasis, which could contribute to tumor
progression [21]. Some hKs are under steroid hormone
regulation and might represent downstream targets
through which hormones affect the initiation or progres-
sion of EOC.
Other data have shown that hK5-hK7 can contribute to
ECM remodeling through fibrinogen, collagen types I and
IV, laminin, and fibronectin and, in this fashion, facilitate
tumor angiogenesis, invasion, and metastasis [21]. Kal-
likreins might also promote angiogenesis by disrupting
ECM barriers. hK2 [44], hK3 [45], hK6 [46], hK7 [27], and
hK14 [41] directly catalyze the hydrolysis of certain ECM
proteins, enabling both EC and tumor cell migration and
invasion. The ECM may also be remodeled through acti-
vation of the uPA-PAR system [21]. For example, hK2 and
hK4 may remodel certain ECM components through plas-
min and release or activate certain pro-angiogenic growth
factors such as vascular endothelial growth factors
(VEGFs) and pro-matrix metalloproteins (MMPs) [47]. It
could be assumed that factor XII and kallikrein family
members might also participate together in the formation
of ascites and peritoneal implants in EOC. Furthermore,
hK1 is expressed in ECs and hK1-generated kinins, which
are multifunctional, biologically active peptides released
from low-molecular-weight kininogen that can stimulate
angiogenesis [48]. The remodeling effect of hKs on ECs
has been demonstrated in Matrigel in vitro invasion
assays. For example, invasion of MDA-MB-231 human
breast cancer cells into Matrigel was suppressed by a syn-
thetic hK1 inhibitor [49], and invasion of LNCaP human
prostate cancer cells through Matrigel was attenuated by
hK3-neutralizing antibodies [45]. Conversely, hK3 has
been shown to have antimetastatic properties in mice
[45]. The antimetastatic effect might be due to an antian-
Table 2: Expression and clinical features of hK members in ovarian cancer
hK family 
member
Location Expression level and site Clinical feature Prognosis
hK4 Tumor cells Increased in EOC tissue Predictive marker for paclitaxel resistance[22] Unfavorable
hK5 Serum, ascites, and tumor 
extracts [23, 24]
Increased on tumor cells and in 
serum and ascites
Potential biomarker for diagnosis Unfavorable
hK6 Tumor cell[26] and 
serum[25]
High in early-stage and low-grade 
tumor tissue and in EOC serum
Overexpression is an early phenomenon in the 
development of ECO; serum level could be 
used as a biomarker
Unfavorable
hK7 Tumor tissue[27] High in late-stage EOC A potential biomarker for diagnosis Unfavorable
hK8 Tumor extract, serum, and 
ascites[29]
High in serum and ascites High level is associated with good prognosis[28, 
29]
Favorable
hK9 Tumor cells[30] High in tumor tissue early-stage and 
optimal debulking patients
Associated with longer progression-free and 
overall survival times
Favorable
hK10 Serum[33] and tumor 
cells[31,32]
High in serum and on tumor cells High serum level is associated with increased 
risk for relapse and death; a potential 
biomarker for diagnosis
Unfavorable
hK11 Serum, ascites[37], and 
tumor extract [34-36]
Increased in tumor samples High level is an independent factor for favorable 
prognosis and is associated with long 
progression-free and overall survival times and 
with slower disease progression[34, 35]; 
however, high level is also associated with poor 
survival rate[36].
Depends
hK13 Tumor tissue[38] verexpressed in tumor tissue Associated with longer progression-free and 
overall survival times
Favorable
hK14 Tumor cells[41] and 
serum[40]
Increased in tumor tissue and 
serum
Associated with longer progression-free and 
overall survival times; an independent 
prognostic factor
Favorable
hK15 Tumor extract[42] Increased in tumor tissue Associated with short progression-free and 
overall survival times; an independent 
prognostic factor
UnfavorablePage 4 of 20
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action. hKs might also be able to promote cancer cell inva-
sion through PAR signaling in a manner similar to
thrombin [50].
According to a study conducted by Rehault, hK2 and hK3
could represent important regulators of insulin-like
growth factors (IGFs) in the proliferation of prostate can-
cer cells [51]; however, similar findings have not been
published on EOC. IGFs are mitogenic peptides that help
regulate normal and malignant cellular proliferation, dif-
ferentiation, apoptosis, and transformation. IGFs have to
be released from IGF-binding proteins (IGFBPs) before
their activation. hK1, hK2, and hK3 are IGFBP proteases
that collectively degrade IGFBPs 2–5 and could abrogate
their affinity for IGF1. In our microarray analysis of the
peritoneum of EOC patients, we detected overexpression
of IGF1 and decreased expression of SPINT2. These find-
ings are important because SPINT2 inhibits the produc-
tion of tissue kallikreins [3]; therefore, it could be deduced
that a high expression of hKs might result. In the mean-
time, IGF1 can stimulate the growth of normal, stromal,
and malignant prostate cells in vitro [51,52]. The IGF-
IGFBP systems can operate in many organs, suggesting
roles for them in cancer growth [53].
The blood coagulation and kallikrein-kinin systems con-
sist of plasmatic proteolytic cascades. These cascades par-
ticipate in the initial host response against foreign
components and in wound healing. The increased expres-
sion of factor XII in the peritoneum tissue of EOC patients
[3] suggests that the intrinsic coagulation cascade is being
activated and may be involved in ovarian carcinoma cell
progression. At least two mechanisms may be responsible
for activating the cascade: the molecular structure of factor
XII mimics the EGF motif and, thus, may have a growth
factor-like role on cancer cells, and because of the positive
feedback loop, the kallikrein system is capable of promot-
ing ovarian cancer cell growth, angiogenesis, metastasis,
and invasion.
Factor XI
Factor XI is a component of the intrinsic coagulation path-
way and is activated after factor XII activation. Factor XI is
the zymogene (i.e., the gene associated with a proteolytic
enzyme) precursor of a plasma serine protease produced
primarily in the liver that contributes to blood coagula-
tion by activating factor IX by limited proteolysis [54].
Factor XI mRNA has been detected in human platelets
[55], but a link between factor XI and the stimulation or
inhibition of cancer cell proliferation and metastasis has
not been established. In our microarray analysis of the
peritoneum of EOC patients, we found a higher expres-
sion of factor XI mRNA in peritoneum and stroma tissue
in the general vicinity of ovarian cancer implants [3].
Because factor XII expression also increased, factor XI
might be induced by the activation of factor XII. In addi-
tion, factor XI might have an indirect role in the pathogen-
esis of cancer by facilitating downstream factors in the
coagulation cascade, such as thrombin and its receptors.
These are discussed later.
Tissue factor
There is abundant evidence that TF plays an important
role in the pathogenesis of cancer. Human TF molecule is
a single-chain, 263-amino-acid, 47-kDa transmembrane
glycoprotein whose primary sequence indicates structural
similarity to members of the cytokine receptor family
[56]. TF is the principal surface receptor and cofactor for
the activated coagulation protease factor VIIa and is a
receptor for its zymogen precursor. The extrinsic coagula-
tion cascade is triggered by the binding of factor VIIa to TF,
which creates a complex for the activation of the protease
factor X and its conversion to factor Xa. Generation of fac-
tor Xa and the TF-factor VIIa complex triggers the proteo-
lytic conversion of factor II (prothrombin) to thrombin.
TF is expressed constitutively on the adventitia of unin-
jured blood vessels and other extravascular tissues [57].
Upregulation of TF gene expression occurs in malignant
cells and in normal host cells that respond to inflamma-
tory or remodeling signals, which might arise from ECs,
MAs, and fibroblasts [58]. Therefore, cytokines and
growth factors, such as platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF), transforming
growth factor-β (TGF-β), and EGF [58], produced by
inflammatory and malignant cells might induce the
expression of TF in fibroblasts and ECs. Experimental evi-
dence has also shown that expression of TF by ECs can be
under the control of VEGF, which can be mediated by the
VEGF receptor fms-like tyrosine kinase (flt-1) and flt-1/
kinase insert domain-containing receptor [59]. Two
downstream components of the coagulation cascade,
thrombin [60] and fibrin [61], can also regulate TF expres-
sion by ECs. Both downregulation and inhibition of TF
expression can modulate tumor cell procoagulant activity.
Recent evidence suggests that TF expression might alter
the cancer cell phenotype and possibly contribute to ang-
iogenesis, proliferation, and metastasis [62-69]. Aberrant
TF expression has been detected in various human
tumors, including EOC [62-64], breast cancer [65], non-
small cell lung cancer [66], colon cancer [67], and pancre-
atic cancer [68] but is not usually found in normal tissues
from these sites. Elevated expression of TF in tumors has
been associated with certain unfavorable prognostic indi-
cators, such as angiogenesis, metastasis, advanced disease
stage, and multidrug resistance [69].Page 5 of 20
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The formation of new cellular masses at an organ site cre-
ates an obvious extra demand for oxygen, growth factors,
and metabolites and increases the need for tumor-associ-
ated blood vessels. The stimulators and inhibitors of ang-
iogenesis that can regulate new vessel formation include
VEGF, acidic and basic FGF, hepatocyte growth factor, and
TGF. Angiostatin, endostatin, and antiangiogenic anti-
thrombin might function as inhibitors of angiogenesis
[70].
Angiogenesis can be mediated by either coagulation-
dependent or-independent activation pathways [71].
Coagulation-dependent pathways always involve activa-
tion of the TF receptor to its ligand, followed by produc-
tion of thrombin and ensuing clot formation.
Coagulation-independent pathways appear to involve
phosphorylation of the cytoplasmic domain of the TF
receptor and subsequent downstream signaling events
that occur independently of thrombin production or clot
formation. Both pathways can contribute to angiogenesis
and tumor progression. Increased expression of TF in
tumors may contribute to angiogenesis in part by increas-
ing VEGF protein expression and downregulating the
expression of the antiangiogenic protein thrombospon-
din [11]. For example, TF-positive colorectal tumors have
higher levels of microvessel density and VEGF expression
than TF-negative colorectal tumors do [67]. Colocaliza-
tion of TF and VEGF mRNA and protein has been demon-
strated in breast cancer, malignant glioma, and
adenocarcinoma of the lung [72]. In the coagulation-
dependent pathway, the interaction of TF and factor VIIa
induces Ca2+ oscillations and changes in gene expression,
and the formation of the TF-factor VIIa complex leads to
the activation of the mitogen-activated protein kinase
(MAPK) pathway [73], which is a major inducer of VEGF
expression. The catalytic activity of the TF-factor VIIa com-
plex contributes to the activation of factor X to factor Xa
and subsequently to thrombin. Factor Xa and thrombin)
can also exert signaling activities through PAR-2 and PAR-
1, respectively. Factor Xa activated by tumor cells may trig-
ger PAR-2 expression as well as formation of TF-factor VIIa
complexes on ECs and may induce intracellular signals;
however, factor Xa exerts the most critical effect in the TF-
factor VIIa-factor Xa complex [74].
In the clotting-independent pathway, the cytoplasmic
domain of TF activates protein kinase C-dependent sign-
aling, in contrast to the ligand-binding extraplasmatic tail
of TF, which upregulates the synthesis of VEGF in
response to different stimuli [75,76]. The cytoplasmic tail
of TF appears to regulate non-clotting-dependent mecha-
nisms such as cytoskeletal reorganization, vascular
remodeling, angiogenesis, and cellular metastasis. Results
from a recent study provided an alternative explanation
whereby TF can promote angiogenesis by a clotting-inde-
pendent mechanism [77]: the genetic deletion of the TF
cytoplasm domain involves the loss of negative regulatory
control with PAR-2 upregulation. Expression of TF and
PAR-2 and the function of TF-PAR-2 signaling pathway
require the presence of both angiogenic growth factors
and inflammatory cytokines. Inflammatory cytokines
produced by monocytes (MO) are important for angio-
genesis and collateral growth vessels. Colocalization of
upregulated PAR-2 with phosphorylated TF occurs only in
neovessels. The phosphorylation of TF appears to be the
mechanism that switches off the negative regulatory con-
trol that promotes pathologic PAR-2-dependent angio-
genesis [77].
However, TF-PAR-2 signaling selectively synergizes with
the PDGF isoform BB but not with VEGF, basic FGF, and
the PDGF isoform AA. PDGF-BB is available through
release from activated platelets in the context of local
coagulation or by synthesis from sprouting ECs. PDGF-BB
also has a role in lymphoangiogenesis. PDGF-BB stimu-
lated MAPK activity and cell motility of isolated lymphatic
ECs in vitro and potently induced the growth of lymphatic
vessels in vivo [78]. Expression of PDGF-BB in murine fib-
rosarcoma cells induced tumor lymphoangiogenesis,
leading to enhanced metastasis in lymph nodes [78].
The cascade of TF-factor VIIa to factor Xa and subse-
quently to thrombin can be inhibited by TF pathway
inhibitor (TFPI), which occurs when the TF-factor VIIa
complex is combined with factor Xa and cell-bound TFPI.
Once this stable quaternary complex is formed, it is trans-
located to and internalized in caveolae (i.e., small vesicles
of the plasma membrane) [79]. Produced by ECs and
tumor cells, most TFPI is expressed on the cell surface,
although it can be detected peripherally in plasma [80]. In
tumor cells, the diminished expression of TFPI could
result in activated factor Xa and increase factor Xa-PAR-2
signaling [81]. Results from in vitro and in vivo studies
have suggested that therapeutic strategies that target an
increase in the expression of TFPI could inhibit tumor
angiogenesis [82], growth [83], and metastasis [53,84].
Another inhibitor of the TF-dependent pathway of blood
coagulation that was recently identified is TFPI-2, which,
in contrast to TFPI, inhibits the TF-factor VIIa complex but
not factor Xa. TFPI-2 also inhibits various proteases [85].
Its expression was lower in laryngeal, breast, gastric,
colon, pancreatic, renal, and endometrial tumor tissues
and glial neoplasms than in normal counterpart tissue
[85]. Some studies have provided evidence of the antian-
giogenic and antimetastatic activity of TFPI-2 [86]. Epige-
netic inactivation of TFPI-2 also contributes to the
progression of pancreatic ductal adenocarcinoma. TFPI-2
mRNA was undetectable in many pancreatic cancer cellPage 6 of 20
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methylation of its promoter CpG island decreased TFPI-2
expression. However, expression of the TFPI-2 gene in
pancreatic cancer cells has resulted in markedly sup-
pressed proliferation, migration, and invasive potential in
vitro [86]. TFPI-2 exerts antitumor effects through antian-
giogenesis and antimetastatic mechanisms [87,88].
TF and metastasis
The role of TF-factor VIIa in metastasis has been exten-
sively investigated. Some recent studies have revealed that
TF can promote the invasion and metastasis of the A2780
human ovarian cancer cell line through the TF-factor VIIa
pathway. In turn, TF-factor VIIa can upregulate the tran-
scription of uPA receptor expression and enhance tumor
invasion and metastasis [63,64]. Overexpression of TF of
up to a 1,000-fold greater level than normal is characteris-
tic of metastatic tumor cells relative to nonmetastatic cells
[89]. Inhibition of TF through antibodies or active site-
blocked factor XIIa interferes with experimental metasta-
sis [90], but how TF on tumor cells contributes to tumor
metastasis is unclear. TF-induced metastasis requires the
participation of the cytoplasmic tail of TF and the assem-
bly of an active TF-factor VIIa complex, which is thought
to target G protein-coupled PAR-2. Factor VIIa induces the
activation of p21Ras and p42/p44 MAPK, which further
induces the activation of the protein kinase B pathway in
TF-expressing cells and increases protein synthesis [91].
Both the p42/p44 MAPK and protein kinase B pathways
are able to inhibit apoptosis. Inhibition of apoptosis may
be related to adhesion-independent survival and thus may
be linked to metastasis. In one study, factor VIIa inhibited
cell death and caspase 3 activation in Baby Hamster Kid-
ney cells induced by serum-deprivation and loss of adhe-
sion (lack of integrin signaling) when transfected with TF
genes [14]. The effects of factor VIIa on caspase 3 activity
are sensitive to inhibitors of the phosphatidylinositol 3'-
kinase and P42/P44 MAPK pathways; thus, factor VIIa
appears to be a survival factor for TF-expressing cells and
seems to mediate the survival of tumor cells during metas-
tasis [14,92].
Another mechanism that links TF effects to metastasis is
mediated by the overexpression of growth factors and pro-
teins related to cellular reorganization. Interleukin (IL)-8,
a member of the CXC chemokine (CXCL8) and a chem-
oattractant for neutrophils and lymphocytes, can act mul-
tifunctionally to induce tumor growth and metastasis, and
IL-8 overexpression can occur through TF-FVIIa stimula-
tion. In contrast, FXa and thrombin cannot upregulate IL-
8 expression. IL-8 leads to increasing cell migration and
invasion, and these effects are attenuated when binding of
factor VIIa to TF is prevented [13]. In ovarian cancer stud-
ies, IL-8 has been suggested to be involved in the forma-
tion of ascites [93,94]. In our peritoneal gene transcript
profile, we showed that IL-8 connects a number of path-
ways that might be linked to the pathogenesis of cancer by
cellspace analysis (Figure 1) [3]. IL-8 may induce other
immune cell-related modulators, such as the IL-13 recep-
tor, vascular cell adhesion molecule 1, chemokine
receptor 1, and other molecules associated with inflam-
matory function [95]. It is known that the inflammatory
response is involved in the progression of tumors and that
IL-8 might amplify inflammation in the tumor microenvi-
ronment to promote tumor cell proliferation, angiogen-
esis, and metastasis.
Thrombin and thrombin receptor
Generation of thrombin is the central step in blood coag-
ulation. Expression of thrombin has been detected in var-
ious tumor types, including ovarian cancer [18].
Thrombin's cellular effect is triggered by its binding to
PARs, which are G protein-coupled receptors, of which
four subtypes have been identified in human tissues. PAR-
1, PAR-3, and PAR-4 are activated mainly by thrombin,
whereas PAR-2 is activated by trypsin, tryptase, factor VIIa,
and factor Xa. PAR-1, the major prototype of the family, is
a receptor with seven transmembrane domains and is acti-
vated by cleavage of a specific site at the N-terminus of its
extracellular domain. The presence of PAR family mem-
bers has been demonstrated on many tumor cells, and it
appears to be positively correlated with metastasis [96].
Studies of proteins at the cellular level (in situ hybridiza-
tion and immunostaining) and studies of gene transcripts
(reverse-transcriptase polymerase chain reaction) have
demonstrated the differential expression pattern of PAR-1
gene in low-grade and high-grade EOC, but PAR-1 expres-
sion has not been shown on normal ovarian tissue even
though the gene was overexpressed in the peritoneum of
EOC patients [3,97]; thus PAR-1 signaling could be
involved in the initiation and pathogenesis of EOC.
Thrombin-PAR system and angiogenesis
Thrombin is a potent activator of angiogenesis and could
be the underlying mechanism for the promotion of tumor
progression after thrombosis. However, evidence suggests
that angiogenesis induced via thrombin is mediated via
PAR and is independent of fibrin formation, which can be
modulated without interfering with blood coagulation
[98]. Thrombin also stimulates the chemotaxis of inflam-
matory cells and thus possibly promotes tumor angiogen-
esis indirectly [98]. Furthermore, thrombin could induce
several cellular effects on ECs, thereby contributing to the
angiogenic cascade.
There are two possible mechanisms by which thrombin
may promote angiogenesis: (1) Thrombin at physiologic
concentrations can inhibit ECs' ability to adhere to colla-
gen type IV or to laminin [99], even after short exposure
of ECs to thrombin. The result is reversible and is medi-Page 7 of 20
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is detachment and migration of ECs from basement mem-
brane components, the initial step in the activation of
normally quiescent ECs. (2) Thrombin upregulates VEGF
expression via PAR activation on ECs or tumor cells [100]
and through release of platelets [101]. Thrombin antago-
nizes any blood vessel-stabilizing effects of angiopoietin 1
by production of angiopoietin 2 [102,103]. The ang-
iogenic effects of thrombin include causing the release of
basic FGF from ECs and the ECM [104]. Thrombin can
also markedly stimulate expression of the VEGF receptor
(kinase insert domain-containing receptor and flt-1). The
activation of protein C kinase and MAPK signaling path-
ways was confirmed in the process of VEGF and VEGF
receptor production [102]. Thrombin may thus contrib-
ute to new vessel formation by providing the pathologic
microenvironment for tumor cell implants and prolifera-
tion; VEGF production through thrombin activation
could facilitate this process. VEGF also increases the per-
meability of existing and new capillary vessels and results
in plasma protein leakage and the development of a
proangiogenic matrix [105]. A high expression level of
VEGF allows the formation of malignant ascites. Thus, the
thrombin-PAR system could play a role in the progression
of ascites in EOC patients by inducing VEGF production.
Thrombin-PAR system in invasion and metastasis
In our peritoneal transcript profile study, we found that
PAR-1 was upregulated in peritoneal tissue, which sug-
gested that this receptor might be involved in EOC patho-
genesis, invasion, and metastasis [3]. Overexpression of
PAR-1 has been reported in malignant invasive melanoma
[106] and breast cancer in vivo [96] and in breast cancer
cell lines [107]. The increase in growth and metastatic
potential of tumor cells may be partly attributable to the
proangiogenic effects of thrombin. By mobilizing adhe-
sion molecules, such as αIIβ3 integrin [108], P-selectin
[109], and CD40 ligand [110], to the cell surface,
thrombin enhances adhesion between tumor cells, plate-
lets, ECs, and ECM and contributes to tumor progression.
Thrombin also triggers the release of growth factors,
chemokines, and ECM proteins that could promote the
proliferation and migration of tumor cells. Facilitation of
the metastatic activity of the thrombin-PAR complex has
been demonstrated in vivo with experimental lung cancer
[111], colon cancer [112], and breast cancer [15,96]. The
principal thrombin receptor, PAR-1, has been implicated
in promoting these effects. Most of the cellular effects elic-
ited by thrombin are mediated through the activation and
subsequent signal transduction cascades of members of
the PAR family. Likewise, thrombin and PAR inhibitors,
Genes associated with MO/MA activationFigure 1
Genes associated with MO/MA activation. This figure was made by cellspace software according to an analysis of the functional 
genes involved in inflammatory response in peritoneal cavity with EOC[3]. The connected lines with different colors show dif-
ferent levels of association among genes. The warmer colors (yellow to red) represent stronger correlations.Page 8 of 20
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small interfering RNAs for PAR-1 [114], have been shown
to prevent tumor migration and metastasis. Thrombin can
also facilitate trans-basement membrane migration by
ECM remodeling after activation of collagen type IV-
degrading enzyme, MMP-2, and αvβ3 integrin. However,
an immunostaining study on EOC found that focal adhe-
sion kinase (FAK), a major tyrosine phosphorylated pro-
tein of adherent cells, was abundantly expressed in
invasive EOC but not in normal ovarian tissues, which is
consistent with a high level of PAR1 expression [97]. Pos-
sibly, PAR1 in malignant ovarian carcinoma transmits sig-
nals leading to the phosphorylation of FAK and thereby to
alterations in integrin expression. Increased expression of
αvβ3 integrin was also detected in our peritoneal profile
study [3]. Anticoagulants such as heparin and warfarin
have been shown to significantly decrease experimentally
induced pulmonary metastasis in vivo [115], and a similar
decrease in tumor cell metastasis was observed in vivo with
hirudin, a highly specific inhibitor for thrombin [15]. In
another study, hirudin inhibited tumor implantation and
growth of four different tumor cell lines (MDA-MB-231
human breast cancer, 4T1 human breast cancer, A549
human non-small cell lung cancer, and B16F10 murine
melanoma) in nude and syngeneic mice by inhibiting
spontaneous seeding of tumors through the blood to sus-
ceptible organs, including the lungs, liver, spleen, and
lymph nodes [15]. Overall, the interaction of endog-
enously generated thrombin and host thrombin receptors
enhances tumor angiogenesis by enhancing the expres-
sion of some genes that may be associated with an inva-
sive profile, and this interaction involves activation of
PAR and other tumor genes.
At least six signal transduction mechanisms based on
thrombin-PAR systems have been proposed to have a role
in invasion and metastasis: (1) PAR may induce phospho-
rylation of FAK and integrin expression [97,116], thereby
contributing to the modulation of cytoskeletal reorganiza-
tion. Changes in cell shape result from changes in actin
stress fibers and focal adhesion and are mediated through
the Rho family of GTPases [117]. Rho-Ras proteins down-
stream of PAR-1 are intermediates of the extracellular sig-
nal-regulated kinases 1 and 2 (ERK1/2)-MAPK pathway
and are implicated in cancer progression [118]. (2) Loss of
activator protein 2 (AP-2) results in the increased expres-
sion of PAR-1, which subsequently contributes to the met-
astatic phenotype of cancer by upregulating the
expression of angiogenic molecules, proteases, and adhe-
sion molecules, which are involved in tumor invasion and
metastasis [119]. This upregulation is based on MAPK sig-
naling. AP-2 is a 52-kDa protein transcription factor
mapped to the short term of chromosome 6, which is a
critical regulator of gene expression during mammalian
development, differentiation, and carcinogenesis. Loss of
AP-2 may contribute to the development and progression
of many different types of cancers, including melanoma
and prostate, breast, and colorectal carcinoma [119]. AP-
2 is a negative regulator for PAR-1 signaling, and func-
tional AP-2-binding elements have been identified in
some genes, including c-erbB2, VEGF, TGF-β, IGFBP-2, E-
cadherin, and c-myc [119]. (3) Overexpression of flotillin-
2, a highly conserved caveolae/lipid raft-associated pro-
tein, is associated with upregulation of PAR-1. Binding of
flotillin-2 to PAR-1 might stabilize it by blocking inactiva-
tion or degradation of an activated PAR-1. Cytoplasmic
flotillin-2 might also modulate PAR-1 trafficking of the
cell or stabilize PAR-1 mRNA, which could promote PAR-
1-induced constitutive signaling through the MAPK or
other signal transduction pathways [120]. (4) PAR-1
cooperates with αvβ5 integrin to promote cytoskeletal
reorganization. Activation of PAR-1 increased the phos-
phorylation of FAK and paxillin and induced the
formation of focal contact complexes. The activation of
PAR-1 may foster tumor cell invasion via a mechanism
involving cooperation with the αvβ5 integrin [116]. (5)
The increased and persistent expression of PAR-1 is
induced by deregulated defective receptor trafficking,
which is correlated with the failure to efficiently downreg-
ulate activated PAR-1 by internalization and lysosomal
sorting [121]. (6) Coexpression of PAR-1 and PAR-2 has
been observed on some tumor cells and the cells of the
tumor microenvironment, such as fibroblasts, platelets,
and ECs. Simultaneous activation of PAR-1 and PAR-2 by
thrombin is required to cause the chemokinetic effect.
Thrombin-induced activation of PAR-2 could play a sub-
tle role in signaling induced by the thrombin-PAR-1 com-
plex and stimulate the motility of metastatic tumor cells
[122].
Platelets can act as bridges between ECs and lymphocytes
or MOs/MAs, and thrombin activation of platelets can
enhance hematogenous metastasis [123]. In addition,
platelet activation and fibrin formation are both impor-
tant mechanisms by which tumor cell-related "procoagu-
lant activity" promotes metastasis. Platelet activation
induced by thrombin is another possible mechanism for
metastasis, though some studies have shown that knock-
out of the PAR-1 and PAR-2 gene of mice does not affect
thrombin signaling in mouse platelets but might attenu-
ate signals in mouse ECs [124,125].
Factor XIII and fibrin
Factor XIII, fibrinogen, and fibrin contribute to the final
step in the coagulation cascade. They are involved in some
pathologic states, including solid tumor growth and the
formation of ascites. Fibrin is formed by thrombin cleav-
age of fibrinopeptides A and B from fibrinogen, exposure
of cryptic polymerization sites, and finally the cleavage of
plasma fibrinogen to fibrin by thrombin. A more stablePage 9 of 20
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is covalently cross-linked to fibrin α and γ chains. Factor
XIII binds to integrin and might also exert antiapoptotic
effects on ECs [16]. In our peritoneal transcript profile
study, the factor XIII gene was upregulated in the perito-
neum and stroma in the vicinity of the tumor [3]. The fac-
tor XIIIa subunit supports the adhesion of platelets
mediated by αIIbβ3 integrin [126] and fibroblasts medi-
ated by αvβ3 integrin and β1-containing integrins [127].
The αvβ3 integrin, one of several integrins upregulated in
the peritoneal transcript profile study [3], is present on
vascular ECs and is a marker for angiogenesis. Factor XIII
might also participate in angiogenesis. Factor XIIIa was
shown to be a mediator of cell adhesion and an inhibitor
of fibrin capillary tube formation in a dose-dependent
manner [16].
Fibrin accumulation within tumors might result from
increased permeability of tumor microvessels, which
would lead to the leakage of plasma proteins, such as
fibrinogen and plasminogen, and extravascular clotting
and the cross-linking of fibrin to factor XIII [7]. In EOC
ascites, high amounts of cross-linked fibrin degradation
products have been identified [128]. VEGF could contrib-
ute to extravascular fibrin clotting in a tumor environ-
ment because it encourages leakage of plasma fibrinogen
into extravascular spaces, where the fibrinogen clots
[128]. Fibrin in the tumor or elsewhere in the peritoneum
and serosa might help stimulate the new ingrowth of
blood vessels. This fibrin gel matrix might also help pro-
vide the matrix that facilitates the ingrowth of MAs and
fibroblasts and reorganizes the stroma, preparing it for
tumor metastasis to the abdominal cavity [129,130].
Ascitic tumor cells as well as tumor cells derived from peri-
toneal and serosal surfaces can retain their viability in sus-
pension cultures [131]. It is interesting that plasma
exudates that contribute to ascites generally remain fluid
and do not form an insoluble fibrin gel until removed
from the patient [131]. Earlier studies showed that hyper-
permeability of peritoneal lining vessels is required for
ascites development in EOC tumors grown in murine
models [132,133]. Cross-linked fibrin staining has not
been observed in the peritoneal wall, diaphragm, mesen-
tery, or bowel serosa of normal controls, but it has been
detected in the peritoneum of ascitic tumor-bearing ani-
mals. Immunostaining revealed that adherent tumor cells
were enmeshed in the fibrin meshwork binding them to
each other and to peritoneal surfaces [129]. We also found
that expression of phospholipase glutaminase A2, which
mediates the first steps in the eicosanoid pathway, was
increased in the peritoneum [3]. Leukotriene products on
this pathway might contribute to capillary permeability
and ascites formation.
Fibrin and angiogenesis
Fibrin-induced neovasculation is based on clotting-
related mechanisms that involve platelet activation and
fibrin deposition. Cross-linked fibrin has been found in
different human malignant tumors. It is present in the
endothelium of angiogenic vessels of invasive cancer spec-
imens but not in vessels of benign tumors [134]. Fibrin
can bind to inflammatory cells or to tumor cells and is
deposited around tumor cells as scaffolding that promotes
further angiogenesis. Fibrinogen and fibrin fragments,
such as fragment E, have been shown to stimulate angio-
genesis both in vitro and in vivo [135]. The presence of the
fibrin degradation product D-dimer is significantly associ-
ated with a poor prognosis in some cancer patients
[136,137].
The binding of ECs to fibrin with the involvement of the
adhesion molecule vascular endothelial cadherin may be
necessary for capillary tube formation, a critical step in
angiogenesis. The fibrin matrix that develops around
tumors provides a provisional proangiogenic environ-
ment that supports vessel formation and stimulates EC
proliferation and migration [138]. The fibrin matrix can
promote a proangiogenic response by upregulating the
expression of αvβ3 integrin receptor to facilitate EC migra-
tion and capillary formation [139]. The αvβ3 integrin pro-
vides survival signals to ECs during their interaction with
fibrin. Tumor-containing tissue has revealed increased
deposition of fibrin stimulated by VEGF-induced vessel
leakiness to sustain the proangiogeneic environment [7].
The fibrin matrix also stimulates the production of VEGF,
basic FGF, IGF1, and IL-8 to promote an autocrine
procoagulant loop by inducing TF expression in ECs [61].
The expression of IGF1 and αvβ3 integrin genes is upregu-
lated in the peritoneum of EOC; therefore, fibrin may
stimulate the production of these genes [3].
Regulatory proteins in the coagulation cascade
Two important regulatory proteins in the coagulation cas-
cade, serine proteinase inhibitor D1 (Serpins, also called
heparin cofactor II – HCII) and endothelial protein C
receptor (EPCR), were first detected as an upexpression in
a study we conducted [3], which suggests that there is
value in studying them further. Serpins are a protein
superfamily of which many members possess potent
activity as serine proteinase inhibitors [140]. Another very
important family of serpins is antithrombins. Both HCII
and antithrombins can inhibit the blood coagulation pro-
teinase thrombin.
HCII is a 480-amino-acid, single-chain glycoprotein with
a molecular weight of about 66 kDa that is synthesized by
the liver and circulates in the plasma. The human HCII
gene is located on chromosome 22q11, spans 15.8 kb,
and includes 5 exons [141]. When HCII interacts withPage 10 of 20
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thrombin can be increased by more than 1,000-fold in
vivo [142]. HCII inactivates thrombin by forming a stable,
bimolecular complex in plasma. HCII does not inhibit
other proteases involved in coagulation or fibrinolysis. It
can also participate in wound healing by regulating the
mitogenic and chemotactic activities of thrombin [143].
Two recent clinical research studies demonstrated that
HCII is a very effective factor in combating heart and vas-
cular disease, which it does by inhibiting the action of
thrombin [144,145]. HCII is inactivated after cleavage of
its reactive site (Leu-444 through Ser-445) by elastase
from leukocytes during the inflammation process without
forming the stable thrombin-HCII complex [146].
HCII has a physiological role in the inflammation
response. An active peptide from the amino-terminal
region (corresponding to Asp-39 through Ile-66) with
chemoattractant action for both neutrophils and MOs is
proteolyzed by neutrophil elastase, and another leukocyte
migration peptide is derived from dodecapeptide from
Asp-49 through Tyr-60 of HCII. HCII-neutrophil protein-
ase products appear to have a role in the local inflamma-
tory response [147]. Leukocytes and MOs/MAs are
important cellular components of tissue injury, wound
healing, and the microenvironment of EOC tumors [6].
The detection of upregulated HCII in the peritoneum and
stroma of EOC patients is interesting because the degrada-
tion of HCII can produce a chemoattractant peptide for
MAs [3]. MOs/MAs have multifunctional roles in EOC
progression by releasing cytokines and chemokines, and
HCII may help induce MA migration from the endothe-
lium to extravascular tissue.
EPCR
EPCR is a 46-kDa type 1 transmembrane glycoprotein
with two domains in the extracellular region that are
homologous to the α1 and α2 domains of CD1/major
histocompatibility complex class I molecules [148]. In
humans, the EPCR gene is located on chromosome
20q11.2. Most EPCRs are expressed on the surface of ECs
of vessels. A 43-kDa soluble EPCR has recently been
found in the plasma of humans [149].
Downstream of coagulation, thrombin stimulates platelet
aggregation, promotes coagulation by cleavage of fibrino-
gen, and fosters fibrin formation and activation of factor
XIII. Thrombin is inhibited via the activated protein C
(APC)-EPCR system. When thrombin binds to thrombo-
modulin on the surface of ECs, it activates protein C
through EPCR to prevent coagulation. APC could inacti-
vate factors V and VIII. The catalytic reaction for protein C
activation by the thrombin-thrombomodulin complex is
inefficient; only after combining with EPCR is protein C
fully activated and does it acquire an anticoagulant role
[150]. In addition to its anticoagulation role, APC inhibits
thrombin-induced proinflammatory activity, such as
platelet activation, cytokine-induced chemotaxis for MOs
and neutrophils, and upregulation of leukocyte adhesion
molecules. APC may prevent inflammation by downregu-
lating TF and tumor necrosis factor-α (TNF-α), nuclear
factor κB translocation, and cytokine signaling from MAs
[151] and by inhibiting TNF-α-induced upregulation of
cell surface leukocyte adhesion molecules [152]. APC may
also protect the vasculature by blocking p53-mediated
apoptosis in ischemic cerebral vasculature [153]. Because
of its anti-inflammatory properties, APC is important in
controlling serious infections. The apoptotic function of
APC is independent of its anticoagulant function and
requires EPCR as a cofactor but is mediated via PAR-1
[154]. When complexed with APC, membrane EPCR,
which is expressed on the surface of ECs, could play a role
in anticoagulation, inhibition of inflammation, and
stimulation of cell proliferation (i.e., antiapoptosis)
[155]. In contrast, soluble EPCR combines with protein C
and APC with the same affinity but inhibits the anticoag-
ulant activity of APC and interferes with the protective
role of membrane EPCR and APC. Soluble EPCR may
bind to and interfere with the function of neutrophil
integrins, such as CD11b/CD18, which facilitates neu-
trophil adhesion to activated ECs and extravasation into
extravascular tissue [156]. Soluble EPCR seems to amplify
the inflammatory response [157,158]. High levels of sol-
uble EPCR have been detected in sepsis [159] and in
autoimmune disease [159]. Results from an animal
model study showed that EPCR expressed on
endothelium had a protective role in the cardiovascular
system [160].
Only two studies relating to EPCR and cancer have been
published [161,162]. Both studies were performed on cell
lines. The membrane protein LMR42 was upregulated in
most multidrug-resistant tumor cells. Expression cloning
and sequence analysis showed LMR42 to be identical to
EPCR. Elevated EPCR expression occurred in 47% of the
primary tumor cell lines, including melanomas and renal
and colon carcinomas. The authors of one of the studies
concluded that elevated expression of EPCR may have a
role in the resistant phenotype of multidrug-resistant
tumor cells [161]. EPCR was also expressed on glioblast-
oma, leukemia, and most breast cancer cell lines;
increased levels of APC activation were observed in tumor
cells that express both EPCR and thrombomodulin [162].
Although the role of EPCR in cancer biology is poorly
understood, it appears that EPCR may contribute to
tumor progression. Our peritoneal transcript profile study
showed high expression of EPCR on EOC peritoneum and
its stroma [3]. PAR-1 is known to mediate a response in
ECs, including the production of platelet-activating factor
and chemokines (e.g., IL-8) and upregulation of adhesionPage 11 of 20
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inflammation, thrombosis, and tumor progression [163].
However, the interaction of APC and PAR-1 is mediated
by EPCR. At physiologic levels, APC is 10,000 times less
potent than thrombin in this PAR-1-mediated pathway.
When EPCR expression is upregulated, APC-PAR-1 signal
transduction is significantly intensified, although it is still
less potent than thrombin in this system [164].
The APC-EPCR interaction provides protection for ECs
through its antiapoptotic effects. Because high EPCR
expression occurs on tumors, EPCR might contribute to
antiapoptosis in tumor cells. Finally, APC can stimulate
PAR-1, whose activation depends on the EPCR concentra-
tion. A PAR-1-associated cellular response might contrib-
ute to tumor progression, possibly by producing IL-8,
which stimulates tumor cell proliferation and metastasis.
The connection between coagulation and inflammation in 
the EOC peritoneum
There is substantial evidence of infiltrating immune cells
in EOC and the peritoneal environment. In a previous
study, we showed that about 70% of T cells within EOC
tumors were mononuclear cells [165]. Results from other
researchers' experiments have suggested that the presence
of these T cells is associated with an antigen-driven
immune response [166-168]. However, there is little evi-
dence to suggest there is a chronic cellular adaptive
immune response in vivo because interferon γ message is
absent or present at low levels [169]. Expression of the
CD3ζ chain was absent or poor in another study [170]. A
recent study showed longer overall and progression-free
survival among EOC patients with intratumoral T cells
than among those lacking these cells [168]. In a more
recent study, CD4+CD25+ regulatory T cells present in
EOC tumors appeared to be associated with poor patient
survival. Regulatory T cells preferentially move to and
accumulate in tumors and ascites but rarely enter the
draining lymph nodes in later cancer stages [171]. Large
numbers of MOs/MAs are also present in ascites, where
they may make up 50% or more of mononuclear leuko-
cytes, whereas the proportion that consists of T lym-
phocytes is usually less than 40% [165]. In recent
preliminary studies, we found that pelvic peritoneal tissue
biopsied from patients with advanced-stage EOC had a
higher proportion of MOs/MAs than T cells even in the
absence of tumor involvement (unpublished data).
Cytokines, chemokines, adhesion molecules, and compo-
nents of the ECM may contribute to a tissue environment
that supports tumor proliferation and invasion. Chemok-
ines and certain cytokines may facilitate the migration of
immune cells, including T cells and MAs, into the tumor
environment (Tables 3 and 4). A network of CC (cysteines
with no intervening amino acid) and CXC chemokines
has been found in solid tumors and in ascites [172]. For
example, CCL2, one of the ligands for CCR2, localizes to
epithelial areas of the tumor [173], and its expression
appears to correlate with the numbers of lymphocytes and
MAs at this site [174]. CCL5 localizes with tumor-infiltrat-
ing leukocytes, and CCL5 concentration may be associ-
ated with CD8+ T cell infiltration. Chemokines CCL2,
CC8, CCL4, CCL5, CCL8, CCL22, CXCL2, and CXCL12
have all been found in increased amounts in ascitic fluid
from EOC patients, and the presence of CCL5 in ascitic
fluid has been associated with the number of T cells in
ascites [175].
Adhesion molecules may also be involved in the implan-
tation of cancers cells onto the peritoneal lining. For
example, E-cadherins and P-cadherins are expressed dur-
ing EOC progression and may facilitate peritoneal inva-
sion because mesothelial cells express cadherin-binding
catenins [4]. Upregulation of discoidin domain receptor
1, claudin 3, and epithelial cell adhesion molecule occurs
early in the development of EOC [176]. Soluble intracel-
lular adhesion molecule 1 concentrations are elevated in
patients with ovarian malignant tumors but do not corre-
late with clinical status[177].
Depending on their degree of expression in the tissue
microenvironment, coagulation and inflammation might
influence each other. Furthermore, components gener-
ated from both the coagulation cascade and an inflamma-
tory response might be involved in heart disease, as
recently reviewed [178-181]. Normal hemostasis is
initiated when the blood vessels rupture, allowing blood
cells to interact with extravascular cells and the ECM
[182]. In one study, endotoxin, TNF-α, and IL-1α induced
TF expression, primarily on MO/MA [58]. Blood clotting
might thus be initiated when inflammatory cytokines and
endotoxin induce the synthesis of TF on migrating leuko-
cytes [183]. In this way, immune cells could help initiate
the coagulation cascade through damaged tissue or
cytokine production [184] (Table 5).
The complement system may also contribute to hemosta-
sis by activating the membrane attack complement path-
way, thereby contributing to phosphatidylserine
expression on the outer membrane of cells [185]. Expres-
sion of phosphatidylserine on the outer cell membrane is
necessary for the effective initiation and amplification of
the coagulation cascade. Our microarray analysis of the
peritoneum of EOC patients showed increased expression
of the C2 component [3]. In contrast, expression of com-
plement HF1, which blocks the membrane attack comple-
ment pathway, was increased and might have shifted the
complement activation pathway toward a proinflamma-
tory response with the recruitment of MO/MA. MO/MA
are also an important source of complement components.Page 12 of 20
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platelets indirectly. Three main chemokines are involved
in this process, CXCL12 (the ligand for CXCR4), CCL17
(the ligand for CCR4), and CCR22 (the ligand for CCR4)
[186]. Platelets are an important link in the inflammation
and coagulation processes. Inflammatory mediators,
cytokines, and chemokines do not increase platelet pro-
duction, but the platelets generated are more thrombo-
genic and thus are more sensitive to platelet agonists such
as thrombin. Platelets contain high concentrations of the
proinflammatory mediator CD40 [187] and certain
chemokines [188]. When CD40 and these chemokines are
released, they can induce TF synthesis and increase the
production of inflammatory cytokines such as IL-6 and IL-
8. Of the naturally occurring anticoagulants, protein C is
the most negatively influenced by inflammation. Throm-
bomodulin and EPCR are both downregulated by inflam-
matory cytokines such as TNF-α [189] and IL-1 [190].
Table 3: Cytokines involved in inflammation in ovarian cancer
Cytokine Effect
TGF-β Stimulates tumor cell attachment and invasion by upregulating plasminogen activator inhibitor type 1
Deregulates expression of the major histocompatibility complex
Deregulates costimulatory antigen expression by dendritic cells
Suppresses Th1-Th2 cells and the conversion of pro-cytotoxic T lymphocytes to cytotoxic T lymphocytes
Suppresses the proliferation response to antigen-presenting cells
Inhibits natural killer and MA activation
IL-6 Upregulates tumor cell attachment
Interferes with macrophage maturation in dendritic cells
Inhibits cell proliferation through PI3K (phosphatidylinositol3-kinase)
Suppresses Th1-Th2 transformation
IL-10 Deregulates expression of major compatibility complex on T cells
Deregulates costimulatory antigen expression
Suppresses cytotoxic T lymphocyte activation and Th1-Th2 transformation
Inhibits interferon production
Inhibits T cell production
VEGF Increases neoangiogenesis, invasion, and metastasis
Increases prevalence of ascites
FGF-2 Increases tumor cell invasion and metastasis
TNF-α Increases adhesion molecule expression
Induces tumor cell apoptosis
Increases tissue factor expression
Decreases the expression of thrombomodulin and EPCR
Table 4: Chemokines involved in ovarian pathogenesis
Chemokine Receptor Cells targeted Comments 
CCL22 CCR4 CD25+CD4+ regulatory T cells Forster tumor immune escape
CCL2 CCR2 Activated T cells, monocytes, and 
DC
Deregulate CD8+ T cells and 
CD68+ macrophage
CCL3 CCR2 Activated T, NK, MO, Eosinophils Inflammatory cells migration
CCL4 CCR5 DC, MO, NK Inflammatory cells migration
CCL5 CCR2 Activated T, NK, MO, Eosinophils Inflammatory cells migration
CCL7 CCR2 Activated T, NK, MO, Eosinophils Inflammatory cells migration
CCL18 Unknown MOs/MAs MA produced but not induced in 
EOC
CXCL8 CXCR1, CXCR2 Neutrophils and resting T cells Angiogenesis, metastasis
CXCL12 CXCR4 Neutrophils, resting T cells, 
activated T and B cells, and 
macrophages
CXCR4 is preferentially expressed 
on EOC cellsPage 13 of 20
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the inflammatory response. For example, it augments leu-
kocyte adhesion and activation, which amplifies the
inflammatory response, and induces endothelium and
platelet activation. The activation of platelets can produce
cytokines (IL-6) and chemokines (IL-8), which are
involved in inflammatory responses [186]. Thrombin also
acts as a direct mitogen for fibroblasts, inducing PDGF
and TGF from platelets and ECs. PDGF and TGF-β are
important cytokines for stimulating neovessel formation,
and TGF-β may contribute to an environment conducive
to tumor escape from immune system surveillance. Nota-
bly, PDGF and TGF-β 3 receptor expression were increased
in our peritoneal transcript profile study [3]; this finding
provides additional evidence that thrombin could foster
tumor cell growth and proliferation via PDGF and TGF
release from platelets and ECs.
Anticancer therapy based on targeting the coagulation 
cascade
Coagulation factors have a profound effect on tumor cell
behavior in both in vivo and in vitro studies. These factors
could enhance tumor cell proliferation, invasion, angio-
genesis, and metastasis. Hence, targeting activated coagu-
lation factors might provide a viable cancer treatment
strategy.
Heparins are the most extensively used anticoagulants in
clinics. In blood coagulation, unfractionated heparin and
low-molecular-weight heparins potentiate the activity of
antithrombin III, thus inhibiting the activation of coagu-
lation factors II and X [191]. They also release TFPI, a
physiologic inhibitor of the TF pathway that prevents pul-
monary embolism and is used to treat deep vein thrombo-
sis [192]. Retrospective and meta-analytic studies of deep
vein thrombosis treatment have shown longer survival
among cancer patients with thrombosis who were treated
with unfractionated heparin and low-molecular-weight
heparins than among patients treated without heparin
[193-198]. Thus, the use of anticoagulants might allow
them to live longer.
There is a higher incidence of venous thromboembolism
in patients with melanoma or small cell lung cancer. In
2003, a pilot study of enoxaprin, a low-molecular-weight
heparin for the treatment of advanced melanoma was
reported [199], but the clinical outcome was not clear.
Then, a phase II trial of combination chemotherapy and
anticoagulant therapy (docetaxel plus enoxaparin) was
performed in chemotherapy-naive patients with meta-
static non-small cell lung cancer [200]. The median time
to progression was 5 months, and the median survival
time was 11 months. The most frequent toxic effects were
neutropenia and asthenia; no clinically significant bleed-
ing or thrombotic events were observed. Treatment was
well tolerated in patients with advanced small cell lung
cancer, and the results suggested that enoxaparin could
prolong the time to disease progression [200]. Both the
oral anticoagulant warfarin and unfractionated heparin
have been shown to prolong survival time among patients
with small cell carcinoma [201].
In 2004, a prospective, randomized, controlled trial
enrolled 385 cancer patients into two arms, placebo and
dalteparin (another low-molecular-weight heparin).
Types of cancer included breast, colorectal, ovarian, and
pancreatic [202]. Thirty-four percent of the dalteparin
group and 31% of the placebo group received chemother-
apy alone; 8% of each group received radiation therapy
alone. Estimated overall survival at 1, 2, and 3 years did
not differ significantly between groups overall. However,
the estimated overall survival among patients with a bet-
ter prognosis at enrollment (55 patients in the dalteparin
group and 47 patients in the placebo group) was signifi-
cantly longer in the dalteparin group at 2 years (78% and
60%; P = 0.03) and at 3 years (55% and 36%; P = 0.03).
In 2005, another study confirmed these antineoplastic
effects of dalteparin [203]. During the 12-month follow-
up period of the study, 602 patients with solid tumors and
venous thromboembolism were randomly assigned to a
dalteparin or coumarin-derivative treatment group.
Among patients without metastatic disease, the
probability of death at 12 months was 20% in the
dalteparin group compared with 36% in the oral antico-
agulant group (P = .03). In patients with metastatic can-
cer, no difference was observed in mortality between the
treatment groups (72% and 69%, P = .46). However, the
observed effects of dalteparin on survival were statistically
significantly different between patients with and without
Table 5: Procoagulant effects of inflammation products
Product Procoagulant effect
Leukocytes or MAs Activate platelets
Induce microvascular occlusion
Release neutrophil elastase
Induce thrombomodulin release from the 
endothelium
Inactivate antithrombin
Complements Increase procoagulant factors production
Provide membrane surfaces
Augment TF expression
Inflammatory Cytokines Increase TF production
Decrease thrombin, EPCR, and protein S 
levels
Increase C-reactive protein production
Increase complement activation
Increase platelet count and reactivity
Chemokines Activate platelet aggregation and adhesion
Attract more leukocytesPage 14 of 20
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to investigate these findings. The exact mechanism by
which heparin mediates antitumor or antimetastatic activ-
ity is unknown but also merits further study.
Conclusion
Factors from the extrinsic and intrinsic coagulation cas-
cades play complex and important roles in cancer progres-
sion by promoting blood clotting; in the
microenvironment of cancer (e.g., ECs, platelets, fibrob-
lasts, leukocytes, and the ECM), altered gene expression
affects key intracellular signaling events. Certain signaling
pathways may facilitate thrombus formation in the peri-
tumoral environment and promote localized angiogen-
esis. In our study of transcript profiles of the peritoneum,
several factors that are part of the intrinsic coagulation
cascade were overexpressed at the transcript level in the
peritoneum in the vicinity of but beyond the periphery of
the tumor [3]. Overall, the extrinsic and intrinsic path-
ways favor clot formation. Thus, products of the perito-
neal environment, which include chemokines, cytokines,
and coagulation factors or their receptors, are evolving as
potential targets for biologic therapy or in vivo diagnostic
tools. The number of humanized monoclonal antibodies
applicable to cancer treatment is increasing as more tar-
gets are discovered. Other approaches to treatment might
include inhibitory oligonucleotides packaged to avoid
degradation and small molecules that block specific path-
ways. Retrospective studies have shown that antithrom-
botic therapy may be associated with a lower incidence of
certain types of cancer [204]. Clinical trials need to be
expanded to target the production of certain coagulation
factors or receptors in the coagulation cascade of
advanced ovarian cancer. Such studies may reveal new
approaches for chemoprevention or combination therapy
that include chemotherapy to control tumor prolifera-
tion, angiogenesis, and metastasis.
References
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer
EJ, Thun MJ: Cancer statistics, 2005.  CA Cancer J Clin 2005,
55:10-30.
2. Feeley KM, Wells M: Precursor lesions of ovarian epithelial
malignancy.  Histopathology 2001, 38:87-95.
3. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M,
Mueller P, Hu W, Savary CA, Kobayashi R, Freedman RS, Marincola
FM: Peritoneal and Subperitoneal Stroma May Facilitate
Regional Spread of Ovarian Cancer.  Clin Cancer Res 2005,
11:113-122.
4. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD: Cad-
herin switching in ovarian cancer progression.  Int J Cancer
2003, 106:172-177.
5. Roskelley CD, Bissell MJ: The dominance of the microenviron-
ment in breast and ovarian cancer.  Semin Cancer Biol 2002,
12:97-104.
6. Freedman RS, Deavers M, Liu J, Wang E: Peritoneal inflammation
- A microenvironment for Epithelial Ovarian Cancer (EOC).
J Transl Med 2004, 2:23.
7. Dvorak HF: Tumors: wounds that do not heal. Similarities
between tumor stroma generation and wound healing.  N
Engl J Med 1986, 315:1650-1659.
8. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L,
Richardson A, Weinberg RA: Reconstruction of functionally nor-
mal and malignant human breast tissues in mice.  Proc Natl
Acad Sci U S A 2004, 101:4966-4971.
9. A. T: Phlegmasia alba dolens: Clinique medicale de l'Hotel-
Dieu de Paris. 2nd ed. paris,.  Fance: JBBalliere et Fils 1865:654-712.
10. Sampson MT, Kakkar AK: Coagulation proteases and human
cancer.  Biochem Soc Trans 2002, 30:201-207.
11. Rickles FR, Levine M, Edwards RL: Hemostatic alterations in can-
cer patients.  Cancer Metastasis Rev 1992, 11:237-248.
12. Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W,
Kudryk BJ: Tumor cell procoagulant and urokinase expression
in carcinoma of the ovary.  J Natl Cancer Inst 1993, 85:1225-1230.
13. Naschitz JE, Yeshurun D, Lev LM: Thromboembolism in cancer.
Changing trends.  Cancer 1993, 71:1384-1390.
14. Schmeidler-Sapiro KT, Ratnoff OD, Gordon EM: Mitogenic Effects
of Coagulation Factor XII and Factor XIIa on HepG2 Cells.
PNAS 1991, 88:4382-4385.
15. Borgono CA, Diamandis EP: The emerging roles of human tissue
kallikreins in cancer.  Nat Rev Cancer 2004, 4:876-890.
16. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Trope C, Saatcioglu F:
Kallikrein 4 is associated with paclitaxel resistance in ovarian
cancer.  Gynecol Oncol 2004, 94:80-85.
17. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas
A, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diaman-
dis EP: Human kallikrein 5: a potential novel serum biomar-
ker for breast and ovarian cancer.  Cancer Res 2003,
63:3958-3965.
18. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A,
Popalis C, Fracchioli S, Katsaros D, Diamandis EP: Parallel overex-
pression of seven kallikrein genes in ovarian cancer.  Cancer
Res 2003, 63:2223-2227.
19. Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn
H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Mas-
sobrio M, Van Der Zee AG, Vergote I, Katsaros D: Human kal-
likrein 6 (hK6): a new potential serum biomarker for
diagnosis and prognosis of ovarian carcinoma.  J Clin Oncol
2003, 21:1035-1043.
20. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS,
Ng SW: Characterisation of human kallikrein 6/protease M
expression in ovarian cancer.  Br J Cancer 2004, 91:725-731.
21. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA: Differential
splicing of KLK5 and KLK7 in epithelial ovarian cancer pro-
duces novel variants with potential as cancer biomarkers.
Clin Cancer Res 2003, 9:1710-1720.
22. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Frac-
chioli S, Danese S, Diamandis EP: The human KLK8 (neuropsin/
ovasin) gene: identification of two novel splice variants and
its prognostic value in ovarian cancer.  Clin Cancer Res 2001,
7:806-811.
23. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B,
Dorn J, Mysliwiec M, Schmitt M, Diamandis EP: Human kallikrein
8, a novel biomarker for ovarian carcinoma.  Cancer Res 2003,
63:2771-2774.
24. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello
B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ,
Richiardi G, Massobrio M, Diamandis EP, Katsaros D: Quantitative
expression of the human kallikrein gene 9 (KLK9) in ovarian
cancer: a new independent and favorable prognostic marker.
Cancer Res 2001, 61:7811-7818.
25. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la
Longrais IA, Howarth DJ, Diamandis EP: Prognostic value of
human kallikrein 10 expression in epithelial ovarian
carcinoma.  Clin Cancer Res 2001, 7:2372-2379.
26. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK,
Mills GB, Bast RCJ, Gershenson DM, Schmandt R: Overexpression
of kallikrein 10 in epithelial ovarian carcinomas.  Gynecol Oncol
2003, 90:44-50.
27. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen
M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee
AG, Vergote I, Diamandis EP: The serum concentration of
human kallikrein 10 represents a novel biomarker for ovar-
ian cancer diagnosis and prognosis.  Cancer Res 2003,
63:807-811.
28. Borgono CA, Fracchioli S, Yousef GM, Rigault de la Longrais IA, Luo
LY, Soosaipillai A, Puopolo M, Grass L, Scorilas A, Diamandis EP, Kat-Page 15 of 20
(page number not for citation purposes)
Journal of Translational Medicine 2005, 3:25 http://www.translational-medicine.com/content/3/1/25saros D: Favorable prognostic value of tissue human kal-
likrein 11 (hK11) in patients with ovarian carcinoma.  Int J
Cancer 2003, 106:605-610.
29. Diamandis EP, Borgono CA, Scorilas A, Harbeck N, Dorn J, Schmitt
M: Human kallikrein 11: an indicator of favorable prognosis
in ovarian cancer patients.  Clin Biochem 2004, 37:823-829.
30. Shigemasa K, Gu L, Tanimoto H, O'Brien TJ, Ohama K: Human kal-
likrein gene 11 (KLK11) mRNA overexpression is associated
with poor prognosis in patients with epithelial ovarian
cancer.  Clin Cancer Res 2004, 10:2766-2770.
31. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Naka-
mura T, Howarth DJ, Yamaguchi N: Human kallikrein 11: a new
biomarker of prostate and ovarian carcinoma.  Cancer Res
2002, 62:295-300.
32. Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt
M, Diamandis EP: Human kallikrein 13 protein in ovarian can-
cer cytosols: a new favorable prognostic marker.  J Clin Oncol
2004, 22:678-685.
33. Kapadia C, Ghosh MC, Grass L, Diamandis EP: Human kallikrein
13 involvement in extracellular matrix degradation.  Biochem
Biophys Res Commun 2004, 323:1084-1090.
34. Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD,
Howarth DH, Fracchioli S, Katsaros D, Diamandis EP: Human kal-
likrein 14: a new potential biomarker for ovarian and breast
cancer.  Cancer Res 2003, 63:9032-9041.
35. Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo
M, Massobrio M, Diamandis EP, Katsaros D: Steroid hormone reg-
ulation and prognostic value of the human kallikrein gene 14
in ovarian cancer.  Am J Clin Pathol 2003, 119:346-355.
36. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono
C, Rigault de la Longrais IA, Puopolo M, Massobrio M, Diamandis EP:
Prognostic value of the human kallikrein gene 15 expression
in ovarian cancer.  J Clin Oncol 2003, 21:3119-3126.
37. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Leder-
mann J, Boshoff C: Predicting biomarkers for ovarian cancer
using gene-expression microarrays.  Br J Cancer 2004,
90:686-692.
38. Deperthes D, Frenette G, Brillard-Bourdet M, Bourgeois L, Gauthier
F, Tremblay RR, Dube JY: Potential involvement of kallikrein
hK2 in the hydrolysis of the human seminal vesicle proteins
after ejaculation.  J Androl 1996, 17:659-665.
39. Webber MM, Waghray A, Bello D: Prostate-specific antigen, a
serine protease, facilitates human prostate cancer cell
invasion.  Clin Cancer Res 1995, 1:1089-1094.
40. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G,
Becker GW, Diamandis EP: Characterization of the enzymatic
activity of human kallikrein 6: Autoactivation, substrate spe-
cificity, and regulation by inhibitors.  Biochem Biophys Res
Commun 2003, 307:948-955.
41. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS: Prostatic human
kallikrein 2 inactivates and complexes with plasminogen
activator inhibitor-1.  Int J Cancer 1999, 81:438-442.
42. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, Straino S,
Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC,
Madeddu P: Local delivery of human tissue kallikrein gene
accelerates spontaneous angiogenesis in mouse model of
hindlimb ischemia.  Circulation 2001, 103:125-132.
43. Wolf WC, Evans DM, Chao L, Chao J: A Synthetic Tissue Kal-
likrein Inhibitor Suppresses Cancer Cell Invasiveness.  Am J
Pathol 2001, 159:1797-1805.
44. Kamath L, Meydani A, Foss F, Kuliopulos A: Signaling from pro-
tease-activated receptor-1 inhibits migration and invasion of
breast cancer cells.  Cancer Res 2001, 61:5933-5940.
45. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier
F, Moreau T: Insulin-like growth factor binding proteins
(IGFBPs) as potential physiological substrates for human
kallikreins hK2 and hK3.  Eur J Biochem 2001, 268:2960-2968.
46. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM,
Hsiung HM, Becker GW, Neubauer BL: Growth regulation of pro-
static stromal cells by prostate-specific antigen.  J Natl Cancer
Inst 1999, 91:1663-1669.
47. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P: Differen-
tial Expression of Protease-Activated Receptors-1 and -2 in
Stromal Fibroblasts of Normal, Benign, and Malignant
Human Tissues.  Am J Pathol 2001, 158:2031-2041.
48. Seligsohn U: Factor XI deficiency.  Thromb Haemost 1993,
70:68-71.
49. Podmore A, Smith M, Savidge G, Alhaq A: Real-time quantitative
PCR analysis of factor XI mRNA variants in human platelets.
J Thromb Haemost 2004, 2:1713-1719.
50. Bazan JF: Structural design and molecular evolution of a
cytokine receptor superfamily.  Proc Natl Acad Sci U S A 1990,
87:6934-6938.
51. Carson SD, Bromberg ME: Tissue factor encryption/de-encryp-
tion is not altered in the absence of the cytoplasmic domain.
Thromb Haemost 2000, 84:657-663.
52. Edgington TS, Mackman N, Brand K, Ruf W: The structural biology
of expression and function of tissue factor.  Thromb Haemost
1991, 66:67-79.
53. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J,
Risau W: The vascular endothelial growth factor receptor Flt-
1 mediates biological activities. Implications for a functional
role of placenta growth factor in monocyte activation and
chemotaxis.  J Biol Chem 1996, 271:17629-17634.
54. Bartha K, Brisson C, Archipoff G, de la Salle C, Lanza F, Cazenave JP,
Beretz A: Thrombin regulates tissue factor and thrombomod-
ulin mRNA levels and activities in human saphenous vein
endothelial cells by distinct mechanisms.  J Biol Chem 1993,
268:421-429.
55. Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL: Fibrin
induction of tissue factor expression in human vascular
endothelial cells.  Circulation 1997, 96:605-613.
56. Fang J, Wei WN, Liu ZP, Song SJ: [Cloning of expression vector
of human tissue factor gene and its expression in human
ovarian cancer cell line].  Zhongguo Shi Yan Xue Ye Xue Za Zhi
2003, 11:579-582.
57. Fang J, Wei WN, Xia LH, Song SJ: [The effects of tissue factor/
activated factor VII complex on the invasion and metastasis
of human ovarian cancer.].  Zhonghua Xue Ye Xue Za Zhi 2004,
25:523-527.
58. Fang J, Wei WN, Xia LH, Song SJ: [Study of the effect of TF/FVIIa
complex on the expression of u-PAR mRNA in human ovar-
ian cancer].  Zhonghua Xue Ye Xue Za Zhi 2004, 25:143-146.
59. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T: Tissue factor
expression in breast cancer tissues: its correlation with prog-
nosis and plasma concentration.  Br J Cancer 2000, 83:164-170.
60. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru
K, Yoshizawa Y: Expression of tissue factor in non-small-cell
lung cancers and its relationship to metastasis.  Br J Cancer
1999, 79:472-477.
61. Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T,
Nakamura S, Shiku H: Expression of tissue factor and vascular
endothelial growth factor is associated with angiogenesis in
colorectal cancer.  Am J Hematol 2002, 69:247-254.
62. Ueda C, Hirohata Y, Kihara Y, Nakamura H, Abe S, Akahane K,
Okamoto K, Itoh H, Otsuki M: Pancreatic cancer complicated
by disseminated intravascular coagulation associated with
production of tissue factor.  J Gastroenterol 2001, 36:848-850.
63. Lwaleed BA, Cooper AJ: Tissue factor expression and multidrug
resistance in cancer: two aspects of a common cellular
response to a hostile milieu.  Med Hypotheses 2000, 55:470-473.
64. Hanahan D, Folkman J: Patterns and emerging mechanisms of
the angiogenic switch during tumorigenesis.  Cell 1996,
86:353-364.
65. Fernandez PM, Rickles FR: Tissue factor and angiogenesis in
cancer.  Curr Opin Hematol 2002, 9:401-406.
66. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern
DM, Nawroth PP: Tissue factor controls the balance of ang-
iogenic and antiangiogenic properties of tumor cells in mice.
J Clin Invest 1994, 94:1320-1327.
67. Shoji M, Abe K, Nawroth PP, Rickles FR: Molecular Mechanisms
Linking Thrombosis and Angiogenesis in Cancer.  Trends in
Cardiovascular Medicine 1997, 7:52-59.
68. Sorensen BB, Freskgard PO, Nielsen LS, Rao LV, Ezban M, Petersen
LC: Factor VIIa-induced p44/42 mitogen-activated protein
kinase activation requires the proteolytic activity of factor
VIIa and is independent of the tissue factor cytoplasmic
domain.  J Biol Chem 1999, 274:21349-21354.
69. Camerer E, Huang W, Coughlin SR: Tissue factor- and factor X-
dependent activation of protease-activated receptor 2 by
factor VIIa.  Proc Natl Acad Sci U S A 2000, 97:5255-5260.Page 16 of 20
(page number not for citation purposes)
Journal of Translational Medicine 2005, 3:25 http://www.translational-medicine.com/content/3/1/2570. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H: Binding of
human factor VIIa to tissue factor induces cytosolic Ca2+ sig-
nals in J82 cells, transfected COS-1 cells, Madin-Darby canine
kidney cells and in human endothelial cells induced to syn-
thesize tissue factor.  J Biol Chem 1995, 270:4650-4660.
71. Camerer E, Rottingen JA, Iversen JG, Prydz H: Coagulation factors
VII and X induce Ca2+ oscillations in Madin-Darby canine
kidney cells only when proteolytically active.  J Biol Chem 1996,
271:29034-29042.
72. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner
A, Carmeliet P, Mueller BM, Friedlander M, Ruf W: Regulation of
angiogenesis by tissue factor cytoplasmic domain signaling.
Nat Med 2004, 10:502-509.
73. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister
B, Ikomi F, Tritsaris K, Dissing S, Ohhashi T, Jackson DG, Cao Y:
PDGF-BB induces intratumoral lymphangiogenesis and pro-
motes lymphatic metastasis.  Cancer Cell 2004, 6:333-345.
74. Sevinsky JR, Rao LV, Ruf W: Ligand-induced protease receptor
translocation into caveolae: a mechanism for regulating cell
surface proteolysis of the tissue factor-dependent coagula-
tion pathway.  J Cell Biol 1996, 133:293-304.
75. Ott I, Miyagi Y, Miyazaki K, Heeb MJ, Mueller BM, Rao LV, Ruf W:
Reversible regulation of tissue factor-induced coagulation by
glycosyl phosphatidylinositol-anchored tissue factor pathway
inhibitor.  Arterioscler Thromb Vasc Biol 2000, 20:874-882.
76. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau
SM: Distribution of tissue factor pathway inhibitor in normal
and malignant human tissues.  Thromb Haemost 1993,
69:366-369.
77. Ahamed J, Belting M, Ruf W: Regulation of tissue factor-induced
signaling by endogenous and recombinant tissue factor path-
way inhibitor-1.  Blood 2004.
78. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE,
Green SJ, Pribluda VS: Tissue factor/factor VIIa inhibitors block
angiogenesis and tumor growth through a nonhemostatic
mechanism.  Cancer Res 2003, 63:2997-3000.
79. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H,
Francis JL: Tissue factor pathway inhibitor reduces experi-
mental lung metastasis of B16 melanoma.  Thromb Haemost
2002, 87:930-936.
80. Sprecher CA, Kisiel W, Mathewes S, Foster DC: Molecular cloning,
expression, and partial characterization of a second human
tissue-factor-pathway inhibitor.  Proc Natl Acad Sci U S A 1994,
91:3353-3357.
81. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA,
Eshleman JR, Goggins M: Epigenetic inactivation of TFPI-2 as a
common mechanism associated with growth and invasion of
pancreatic ductal adenocarcinoma.  Oncogene 2004.
82. Chand HS, Du X, Ma D, Inzunza HD, Kamei S, Foster D, Brodie S,
Kisiel W: The effect of human tissue factor pathway inhibitor-
2 on the growth and metastasis of fibrosarcoma tumors in
athymic mice.  Blood 2004, 103:1069-1077.
83. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S, Rao JS:
Expression of tissue factor pathway inhibitor 2 inversely cor-
relates during the progression of human gliomas.  Clin Cancer
Res 2001, 7:570-576.
84. Mueller BM, Reisfeld RA, Edgington TS, Ruf W: Expression of tissue
factor by melanoma cells promotes efficient hematogenous
metastasis.  Proc Natl Acad Sci U S A 1992, 89:11832-11836.
85. Mueller BM, Ruf W: Requirement for binding of catalytically
active factor VIIa in tissue factor-dependent experimental
metastasis.  J Clin Invest 1998, 101:1372-1378.
86. Versteeg HH, Sorensen BB, Slofstra SH, Van den Brande JH, Stam JC,
van Bergen en Henegouwen PM, Richel DJ, Petersen LC, Peppelen-
bosch MP: VIIa/tissue factor interaction results in a tissue fac-
tor cytoplasmic domain-independent activation of protein
synthesis, p70, and p90 S6 kinase phosphorylation.  J Biol Chem
2002, 277:27065-27072.
87. Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP: Coagulation
factors VIIa and Xa inhibit apoptosis and anoikis.  Oncogene
2004, 23:410-417.
88. Sorensen BB, Rao LV, Tornehave D, Gammeltoft S, Petersen LC:
Antiapoptotic effect of coagulation factor VIIa.  Blood 2003,
102:1708-1715.
89. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL,
Mandal SK, Pendurthi UR, Rao LV: Tissue factor-factor VIIa-spe-
cific up-regulation of IL-8 expression in MDA-MB-231 cells is
mediated by PAR-2 and results in increased cell migration.
Blood 2004, 103:3029-3037.
90. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen
GB, Trope CG, Bryne M, Risberg B, van de Putte G, Goldberg I:
Interleukin-8 and vascular endothelial growth factor mRNA
and protein levels are down-regulated in ovarian carcinoma
cells in serous effusions.  Clin Exp Metastasis 2002, 19:135-144.
91. Gawrychowski K, Skopinska-Rozewska E, Barcz E, Sommer E, Sza-
niawska B, Roszkowska-Purska K, Janik P, Zielinski J: Angiogenic
activity and interleukin-8 content of human ovarian cancer
ascites.  Eur J Gynaecol Oncol 1998, 19:262-264.
92. Mukaida N: Pathophysiological roles of interleukin-8/CXCL8
in pulmonary diseases.  Am J Physiol Lung Cell Mol Physiol 2003,
284:L566-77.
93. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginz-
burg Y, Reich R, Vlodavsky I, Bar-Shavit R: Thrombin receptor
overexpression in malignant and physiological invasion
processes.  Nat Med 1998, 4:909-914.
94. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit
R: Differential expression of Protease activated receptor 1
(Par1) and pY397FAK in benign and malignant human ovar-
ian tissue samples.  Int J Cancer 2005, 113:372-378.
95. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME: Thrombin
promotes angiogenesis by a mechanism independent of
fibrin formation.  Am J Physiol 1993, 264:C1302-7.
96. Tsopanoglou NE, Maragoudakis ME: On the mechanism of
thrombin-induced angiogenesis: inhibition of attachment of
endothelial cells on basement membrane components.  Ang-
iogenesis 1998, 1:192-200.
97. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Waki-
maru N, Nakata M, Kitajima I, Maruyama I: The role of thrombin
in the neo-vascularization of malignant gliomas: an intrinsic
modulator for the up-regulation of vascular endothelial
growth factor.  Int J Oncol 2002, 20:921-928.
98. Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive
production and thrombin-induced release of vascular
endothelial growth factor by human megakaryocytes and
platelets.  Proc Natl Acad Sci U S A 1997, 94:663-668.
99. Tsopanoglou NE, Maragoudakis ME: On the mechanism of
thrombin-induced angiogenesis. Potentiation of vascular
endothelial growth factor activity on endothelial cells by up-
regulation of its receptors.  J Biol Chem 1999, 274:23969-23976.
100. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S: Thrombin induces
increased expression and secretion of angiopoietin-2 from
human umbilical vein endothelial cells.  Blood 2002,
99:1646-1650.
101. Herbert JM, Dupuy E, Laplace MC, Zini JM, Bar Shavit R, Tobelem G:
Thrombin induces endothelial cell growth via both a proteo-
lytic and a non-proteolytic pathway.  Biochem J 1994, 303 ( Pt
1):227-231.
102. Coughlin SR: Thrombin signalling and protease-activated
receptors.  Nature 2000, 407:258-264.
103. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, D'And-
rea MR, Andrade-Gordon P, Karpatkin S: Protease-activated
receptor 1 (PAR-1) is required and rate-limiting for
thrombin-enhanced experimental pulmonary metastasis.
Blood 1998, 92:3694-3700.
104. Henrikson KP, Salazar SL, Fenton JW, Pentecost BT: Role of
thrombin receptor in breast cancer invasiveness.  Br J Cancer
1999, 79:401-406.
105. Hughes PE, Pfaff M: Integrin affinity modulation.  Trends Cell Biol
1998, 8:359-364.
106. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF: A
platelet alpha-granule membrane protein (GMP-140) is
expressed on the plasma membrane after activation.  J Cell
Biol 1985, 101:880-886.
107. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-
Berghaus G, Kroczek RA: CD40 ligand on activated platelets
triggers an inflammatory reaction of endothelial cells.  Nature
1998, 391:591-594.
108. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S: Thrombin stimu-
lates tumor-platelet adhesion in vitro and metastasis in vivo.
J Clin Invest 1991, 87:229-236.
109. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M: Aberrant
expression and activation of the thrombin receptor pro-Page 17 of 20
(page number not for citation purposes)
Journal of Translational Medicine 2005, 3:25 http://www.translational-medicine.com/content/3/1/25tease-activated receptor-1 induces cell proliferation and
motility in human colon cancer cells.  Am J Pathol 2003,
162:1503-1513.
110. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S: Role of
endogenous thrombin in tumor implantation, seeding, and
spontaneous metastasis.  Blood 2004, 104:2746-2751.
111. Asanuma K, Wakabayashi H, Hayashi T, Okuyama N, Seto M, Mat-
sumine A, Kusuzaki K, Suzuki K, Uchida A: Thrombin inhibitor,
argatroban, prevents tumor cell migration and bone
metastasis.  Oncology 2004, 67:166-173.
112. Liu J, Schuff-Werner P, Steiner M: Double transfection improves
small interfering RNA-induced thrombin receptor (PAR-1)
gene silencing in DU 145 prostate cancer cells.  FEBS Lett 2004,
577:175-180.
113. Walz DA, Fenton JW: The role of thrombin in tumor cell
metastasis.  Invasion Metastasis 1994, 14:303-308.
114. Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P,
Altevogt P, Bar-Shavit R: Tumor cell invasion is promoted by
activation of protease activated receptor-1 in cooperation
with the alpha vbeta 5 integrin.  J Biol Chem 2001,
276:10952-10962.
115. Vial E, Sahai E, Marshall CJ: ERK-MAPK signaling coordinately
regulates activity of Rac1 and RhoA for tumor cell motility.
Cancer Cell 2003, 4:67-79.
116. Conner SR, Scott G, Aplin AE: Adhesion-dependent activation of
the ERK1/2 cascade is by-passed in melanoma cells.  J Biol
Chem 2003, 278:34548-34554.
117. Tellez C, Bar-Eli M: Role and regulation of the thrombin recep-
tor (PAR-1) in human melanoma.  Oncogene 2003,
22:3130-3137.
118. Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, Bar-
Eli M, Duvic M: Up-regulation of Flotillin-2 is associated with
melanoma progression and modulates expression of the
thrombin receptor protease activated receptor 1.  Cancer Res
2004, 64:7361-7369.
119. Booden MA, Eckert LB, Der CJ, Trejo J: Persistent signaling by
dysregulated thrombin receptor trafficking promotes breast
carcinoma cell invasion.  Mol Cell Biol 2004, 24:1990-1999.
120. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM: Protease-acti-
vated receptors (PAR1 and PAR2) contribute to tumor cell
motility and metastasis.  Mol Cancer Res 2004, 2:395-402.
121. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Cough-
lin SR: Platelets, protease-activated receptors, and fibrinogen
in hematogenous metastasis.  Blood 2004, 104:397-401.
122. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR: Genetic evi-
dence that protease-activated receptors mediate factor Xa
signaling in endothelial cells.  J Biol Chem 2002, 277:16081-16087.
123. Kataoka H, Hamilton JR, McKemy DD, Camerer E, Zheng YW, Cheng
A, Griffin C, Coughlin SR: Protease-activated receptors 1 and 4
mediate thrombin signaling in endothelial cells.  Blood 2003,
102:3224-3231.
124. Dallabrida SM, Falls LA, Farrell DH: Factor XIIIa supports micro-
vascular endothelial cell adhesion and inhibits capillary tube
formation in fibrin.  Blood 2000, 95:2586-2592.
125. Cox AD, Devine DV: Factor XIIIa binding to activated platelets
is mediated through activation of glycoprotein IIb-IIIa.  Blood
1994, 83:1006-1016.
126. Barry EL, Mosher DF: Binding and degradation of blood coagu-
lation factor XIII by cultured fibroblasts.  J Biol Chem 1990,
265:9302-9307.
127. Wilhelm O, Hafter R, Henschen A, Schmitt M, Graeff H: Role of
plasmin in the degradation of the stroma-derived fibrin in
human ovarian carcinoma.  Blood 1990, 75:1673-1678.
128. Nagy JA, Meyers MS, Masse EM, Herzberg KT, Dvorak HF: Patho-
genesis of ascites tumor growth: fibrinogen influx and fibrin
accumulation in tissues lining the peritoneal cavity.  Cancer
Res 1995, 55:369-375.
129. Nagy JA, Morgan ES, Herzberg KT, Manseau EJ, Dvorak AM, Dvorak
HF: Pathogenesis of ascites tumor growth: angiogenesis, vas-
cular remodeling, and stroma formation in the peritoneal
lining.  Cancer Res 1995, 55:376-385.
130. van de Molengraft F, Jap P, Poels L, Croes H, Vooijs P: Tumor cell
settling and early invasion of the peritoneum.  Clin Exp
Metastasis 1989, 7:187-199.
131. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK,
Sioussat TM, Dvorak HF: Pathogenesis of ascites tumor growth:
vascular permeability factor, vascular hyperpermeability,
and ascites fluid accumulation.  Cancer Res 1995, 55:360-368.
132. Nagy JA, Herzberg KT, Masse EM, Zientara GP, Dvorak HF:
Exchange of macromolecules between plasma and perito-
neal cavity in ascites tumor-bearing, normal, and serotonin-
injected mice.  Cancer Res 1989, 49:5448-5458.
133. Contrino J, Hair G, Kreutzer DL, Rickles FR: In situ detection of
tissue factor in vascular endothelial cells: correlation with
the malignant phenotype of human breast disease.  Nat Med
1996, 2:209-215.
134. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE: Fibrino-
gen E-fragment inhibits the migration and tubule formation
of human dermal microvascular endothelial cells in vitro.
Cancer Res 2000, 60:4719-4724.
135. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van
Dam P, Prove A, Lemmens J, Vermeulen P: Plasma fibrin D-dimer
levels correlate with tumour volume, progression rate and
survival in patients with metastatic breast cancer.  Br J Cancer
2002, 86:389-395.
136. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD,
Dewhirst M, Greenberg C: Plasma D-dimer levels in operable
breast cancer patients correlate with clinical stage and axil-
lary lymph node status.  J Clin Oncol 2000, 18:600-608.
137. van Hinsbergh VW, Collen A, Koolwijk P: Role of fibrin matrix in
angiogenesis.  Ann N Y Acad Sci 2001, 936:426-437.
138. Clark RA, Tonnesen MG, Gailit J, Cheresh DA: Transient func-
tional expression of alphaVbeta 3 on vascular cells during
wound repair.  Am J Pathol 1996, 148:1407-1421.
139. Maekawa H, Sato H, Tollefsen DM: Thrombin inhibition by HCII
in the presence of elastase-cleaved HCII and thrombin-HCII
complex.  Thromb Res 2000, 100:443-451.
140. Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM:
Complete nucleotide sequence of the gene for human
heparin cofactor II and mapping to chromosomal band
22q11.  Biochemistry 1991, 30:1350-1357.
141. Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW,
Andrew M, Delorme M, Ginsberg J, Preissner KT, et al.: Inhibition
of thrombin by antithrombin III and heparin cofactor II in
vivo.  Thromb Haemost 1995, 73:405-412.
142. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM: Heparin
cofactor II inhibits arterial thrombosis after endothelial
injury.  J Clin Invest 2002, 109:213-219.
143. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M,
Tamura K, Matsumoto T: High plasma heparin cofactor II activ-
ity is associated with reduced incidence of in-stent restenosis
after percutaneous coronary intervention.  Circulation 2004,
109:481-486.
144. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M,
Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase
T, Kondo A, Matsumoto T: Heparin cofactor II is a novel protec-
tive factor against carotid atherosclerosis in elderly
individuals.  Circulation 2004, 109:2761-2765.
145. Pratt CW, Tobin RB, Church FC: Interaction of heparin cofactor
II with neutrophil elastase and cathepsin G.  J Biol Chem 1990,
265:6092-6097.
146. Church FC, Pratt CW, Hoffman M: Leukocyte chemoattractant
peptides from the serpin heparin cofactor II.  J Biol Chem 1991,
266:704-709.
147. Simmonds RE, Lane DA: Structural and functional implications
of the intron/exon organization of the human endothelial
cell protein C/activated protein C receptor (EPCR) gene:
comparison with the structure of CD1/major histocompati-
bility complex alpha1 and alpha2 domains.  Blood 1999,
94:632-641.
148. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT: Identifica-
tion of functional endothelial protein C receptor in human
plasma.  J Clin Invest 1997, 100:411-418.
149. Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K,
Mizokami H, Kimoto M: Activation mechanism of anticoagulant
protein C in large blood vessels involving the endothelial cell
protein C receptor.  J Exp Med 1998, 187:1029-1035.
150. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW: Gene
expression profile of antithrombotic protein c defines new
mechanisms modulating inflammation and apoptosis.  J Biol
Chem 2001, 276:11199-11203.Page 18 of 20
(page number not for citation purposes)
Journal of Translational Medicine 2005, 3:25 http://www.translational-medicine.com/content/3/1/25151. Van de Wouwer M, Collen D, Conway EM: Thrombomodulin-
protein C-EPCR system: integrated to regulate coagulation
and inflammation.  Arterioscler Thromb Vasc Biol 2004,
24:1374-1383.
152. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED,
Fukudome K, Zlokovic BV: Activated protein C blocks p53-
mediated apoptosis in ischemic human brain endothelium
and is neuroprotective.  Nat Med 2003, 9:338-342.
153. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation
of endothelial cell protease activated receptor 1 by the pro-
tein C pathway.  Science 2002, 296:1880-1882.
154. Esmon CT: Structure and functions of the endothelial cell pro-
tein C receptor.  Crit Care Med 2004, 32:S298-301.
155. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ: The soluble
endothelial protein C receptor binds to activated neu-
trophils: involvement of proteinase-3 and CD11b/CD18.  J
Immunol 2000, 165:4697-4703.
156. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S: A
haplotype of the EPCR gene is associated with increased
plasma levels of sEPCR and is a candidate risk factor for
thrombosis.  Blood 2004, 103:1311-1318.
157. Medina P, Navarro S, Estelles A, Vaya A, Woodhams B, Mira Y, Villa
P, Migaud-Fressart M, Ferrando F, Aznar J, Bertina RM, Espana F:
Contribution of polymorphisms in the endothelial protein C
receptor gene to soluble endothelial protein C receptor and
circulating activated protein C levels, and thrombotic risk.
Thromb Haemost 2004, 91:905-911.
158. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della
Valle P, Esmon CT: Plasma levels of endothelial cell protein C
receptor are elevated in patients with sepsis and systemic
lupus erythematosus: lack of correlation with thrombomod-
ulin suggests involvement of different pathological
processes.  Blood 1998, 91:725-727.
159. Iwaki T, Cruz DT, Martin JA, Castellino FJ: A cardioprotective role
for the endothelial protein C receptor in lipopolysaccharide-
induced endotoxemia in the mouse.  Blood 2004.
160. Scheffer GL, Flens MJ, Hageman S, Izquierdo MA, Shoemaker RH,
Scheper RJ: Expression of the vascular endothelial cell protein
C receptor in epithelial tumour cells.  Eur J Cancer 2002,
38:1535-1542.
161. Tsuneyoshi N, Fukudome K, Horiguchi S, Ye X, Matsuzaki M, Toi M,
Suzuki K, Kimoto M: Expression and anticoagulant function of
the endothelial cell protein C receptor (EPCR) in cancer cell
lines.  Thromb Haemost 2001, 85:356-361.
162. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L:
Potential mechanisms for a proinflammatory vascular
cytokine response to coagulation activation.  J Immunol 1998,
160:5130-5135.
163. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon N, Esmon CT, Coughlin
SR: PAR1 cleavage and signaling in response to activated pro-
tein C and thrombin.  J Biol Chem 2005.
164. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL,
Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Tem-
plin S, Scott W, Platsoucas CD: Clinical and biological effects of
intraperitoneal injections of recombinant interferon-gamma
and recombinant interleukin 2 with or without tumor-infil-
trating lymphocytes in patients with ovarian or peritoneal
carcinoma.  Clin Cancer Res 2000, 6:2268-2278.
165. Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Car-
rasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S: Intra-
peritoneal adoptive immunotherapy of ovarian carcinoma
with tumor-infiltrating lymphocytes and low-dose recom-
binant interleukin-2: a pilot trial.  J Immunother Emphasis Tumor
Immunol 1994, 16:198-210.
166. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A,
Edwards CL, Platsoucas CD: Large-scale expansion in inter-
leukin-2 of tumor-infiltrating lymphocytes from patients
with ovarian carcinoma for adoptive immunotherapy.  J
Immunol Methods 1994, 167:145-160.
167. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M,
Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN,
Rubin SC, Coukos G: Intratumoral T cells, recurrence, and sur-
vival in epithelial ovarian cancer.  N Engl J Med 2003,
348:203-213.
168. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschrae-
gen CF, Platsoucas CD, Freedman RS: Differential expression of
cytokine transcripts in human epithelial ovarian carcinoma
by solid tumour specimens, peritoneal exudate cells contain-
ing tumour, tumour-infiltrating lymphocyte (TIL)-derived T
cell lines and established tumour cell lines.  Clin Exp Immunol
1998, 112:172-180.
169. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M,
Edwards R, Whiteside TL: Expression of cytokine genes or pro-
teins and signaling molecules in lymphocytes associated with
human ovarian carcinoma.  Int J Cancer 1996, 68:276-284.
170. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evde-
mon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S,
Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knut-
son KL, Chen L, Zou W: Specific recruitment of regulatory T
cells in ovarian carcinoma fosters immune privilege and pre-
dicts reduced survival.  Nat Med 2004, 10:942-949.
171. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt
B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A,
Van Damme J: Identification of biologically active chemokine
isoforms from ascitic fluid and elevated levels of CCL18/pul-
monary and activation-regulated chemokine in ovarian
carcinoma.  J Biol Chem 2002, 277:24584-24593.
172. Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S,
Allavena P, Sozzani S, Mantovani A, Balkwill FR: The detection and
localization of monocyte chemoattractant protein-1 (MCP-
1) in human ovarian cancer.  J Clin Invest 1995, 95:2391-2396.
173. Negus RP, Stamp GW, Hadley J, Balkwill FR: Quantitative assess-
ment of the leukocyte infiltrate in ovarian cancer and its
relationship to the expression of C-C chemokines.  Am J Pathol
1997, 150:1723-1734.
174. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J: Analysis of chem-
okines and chemokine receptor expression in ovarian cancer
ascites.  Clin Cancer Res 2002, 8:1108-1114.
175. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry
J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG,
Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien
PM: Overexpression of the cell adhesion molecules DDR1,
Claudin 3, and Ep-CAM in metaplastic ovarian epithelium
and ovarian cancer.  Clin Cancer Res 2004, 10:4427-4436.
176. Opala T, Drews K, Rzymski P, Wozniak J, Sajdak S: Evaluation of
soluble intracellular adhesion molecule-1 (sICAM-1) in
benign and malignant ovarian masses.  Eur J Gynaecol Oncol
2003, 24:255-257.
177. Esmon CT: Inflammation and thrombosis.  J Thromb Haemost
2003, 1:1343-1348.
178. Esmon CT: Coagulation and inflammation.  J Endotoxin Res 2003,
9:192-198.
179. Esmon CT: Interactions between the innate immune and
blood coagulation systems.  Trends Immunol 2004, 25:536-542.
180. Esmon CT: Crosstalk between inflammation and thrombosis.
Maturitas 2004, 47:305-314.
181. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badi-
mon JJ, Himber J, Riederer MA, Nemerson Y: Blood-borne tissue
factor: another view of thrombosis.  Proc Natl Acad Sci U S A
1999, 96:2311-2315.
182. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer
MA, Nemerson Y: Transfer of tissue factor from leukocytes to
platelets is mediated by CD15 and tissue factor.  Blood 2000,
96:170-175.
183. Esmon CT: The impact of the inflammatory response on
coagulation.  Thromb Res 2004, 114:321-327.
184. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ: Complement proteins
C5b-9 cause release of membrane vesicles from the platelet
surface that are enriched in the membrane receptor for
coagulation factor Va and express prothrombinase activity.
J Biol Chem 1988, 263:18205-18212.
185. Gear AR, Camerini D: Platelet chemokines and chemokine
receptors: linking hemostasis, inflammation, and host
defense.  Microcirculation 2003, 10:335-350.
186. Miller DL, Yaron R, Yellin MJ: CD40L-CD40 interactions regu-
late endothelial cell surface tissue factor and thrombomod-
ulin expression.  J Leukoc Biol 1998, 63:373-379.
187. Fujisawa T, Fujisawa R, Kato Y, Nakayama T, Morita A, Katsumata H,
Nishimori H, Iguchi K, Kamiya H, Gray PW, Chantry D, Suzuki R,
Yoshie O: Presence of high contents of thymus and activation-
regulated chemokine in platelets and elevated plasma levels
of thymus and activation-regulated chemokine and macro-Page 19 of 20
(page number not for citation purposes)
Journal of Translational Medicine 2005, 3:25 http://www.translational-medicine.com/content/3/1/25Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
phage-derived chemokine in patients with atopic dermatitis.
J Allergy Clin Immunol 2002, 110:139-146.
188. Fukudome K, Esmon CT: Identification, cloning, and regulation
of a novel endothelial cell protein C/activated protein C
receptor.  J Biol Chem 1994, 269:26486-26491.
189. Conway EM, Rosenberg RD: Tumor necrosis factor suppresses
transcription of the thrombomodulin gene in endothelial
cells.  Mol Cell Biol 1988, 8:5588-5592.
190. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM: Low-
molecular-weight heparins compared with unfractionated
heparin for treatment of acute deep venous thrombosis. A
meta-analysis of randomized, controlled trials.  Ann Intern Med
1999, 130:800-809.
191. Abildgaard U: Heparin/low molecular weight heparin and tis-
sue factor pathway inhibitor.  Haemostasis 1993, 23 Suppl
1:103-106.
192. Green D, Hull RD, Brant R, Pineo GF: Lower mortality in cancer
patients treated with low-molecular-weight versus standard
heparin.  Lancet 1992, 339:1476.
193. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS: Low-molecular-
weight heparins and unfractionated heparin in the treat-
ment of patients with acute venous thromboembolism:
results of a meta-analysis.  Am J Med 1996, 100:269-277.
194. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH,
Buller HR: Do heparins do more than just treat thrombosis?
The influence of heparins on cancer spread.  Thromb Haemost
1999, 82:947-952.
195. Cosgrove RH, Zacharski LR, Racine E, Andersen JC: Improved can-
cer mortality with low-molecular-weight heparin treatment:
a review of the evidence.  Semin Thromb Hemost 2002, 28:79-87.
196. Kakkar AK, Williamson RC: Antithrombotic therapy in cancer.
Bmj 1999, 318:1571-1572.
197. Zacharski LR, Ornstein DL, Mamourian AC: Low-molecular-
weight heparin and cancer.  Semin Thromb Hemost 2000, 26
Suppl 1:69-77.
198. Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski
LR: Low molecular weight heparin treatment for malignant
melanoma: a pilot clinical trial.  Thromb Haemost 2003,
89:405-407.
199. Robert F, Busby E, Marques MB, Reynolds RE, Carey DE: Phase II
study of docetaxel plus enoxaparin in chemotherapy-naive
patients with metastatic non-small cell lung cancer: prelimi-
nary results.  Lung Cancer 2003, 42:237-245.
200. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJJ,
Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donnell JF, et al.:
Effect of warfarin anticoagulation on survival in carcinoma of
the lung, colon, head and neck, and prostate. Final report of
VA Cooperative Study #75.  Cancer 1984, 53:2046-2052.
201. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK,
Rustin G, Thomas M, Quigley M, Williamson RCN: Low Molecular
Weight Heparin, Therapy With Dalteparin, and Survival in
Advanced Cancer: The Fragmin Advanced Malignancy Out-
come Study (FAMOUS).  J Clin Oncol 2004, 22:1944-1948.
202. Lee AYY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar
AK, Prins M, Levine MN: Randomized Comparison of Low
Molecular Weight Heparin and Coumarin Derivatives on the
Survival of Patients With Cancer and Venous
Thromboembolism.  J Clin Oncol 2005:JCO.2005.03.133.
203. Schulman S, Lindmarker P: Incidence of cancer after prophylaxis
with warfarin against recurrent venous thromboembolism.
Duration of Anticoagulation Trial.  N Engl J Med 2000,
342:1953-1958.Page 20 of 20
(page number not for citation purposes)
